Giuseppe V, Masucci

About me
Publications
Grants
CV
Public outreach and news

About me

Giuseppe Masucci is a professor affiliated with the Department of Oncology-Pathology at Karolinska Institutet in Stockholm, Sweden. His research and clinical work focus on advancing cancer treatment, particularly in the field of onco-immunotherapy.
Research and Expertise
Professor Masucci leads the Onco-Immunotherapy Innovation and Research Unit (OITIRU) at Karolinska Institutet. His work encompasses:
Developing innovative approaches to cancer therapy
Applying machine learning and AI to optimize cancer treatment
Creating algorithms for personalized cancer prognosis and treatment plans
Notable Achievements
Algorithm Development: Professor Masucci has developed an algorithm to define more accurate prognoses and personalized treatment plans for cancer patients. This work aims to create a generalized, user-friendly model for clinicians worldwide.
Publication Record: He has an extensive publication history in high-impact journals, with numerous articles in prestigious oncology and immunotherapy publications.
Professional Experience
Clinician at the Oncological department since 1978
Associated Professor (Docent) at Karolinska Institute
Overseeing physician (Överläkare) at Karolinska University Hospital
Collaborative Approach
Professor Masucci is known for his collaborative spirit and interdisciplinary approach. He actively seeks partnerships with bioinformatics experts and statisticians to enhance his research.
His work often involves:
Integrating clinical expertise with advanced statistical methods
Applying machine learning technologies to validate and improve medical models
Fostering creative partnerships to drive innovation in cancer research
Current Focus
Professor Masucci is currently working on refining and expanding his statistical model for cancer treatment optimization. This ongoing project aims to improve cancer therapy outcomes by leveraging data-driven approaches and personalized medicine strategies.
Giuseppe Masucci's work at Karolinska Institutet represents a significant contribution to the field of oncology, combining clinical experience with cutting-edge technology to advance cancer treatment and improve patient outcomes.

Research

Cancer Immunotherapy
Professor Masucci is heavily involved in cancer immunotherapy research, particularly:
Leading the Onco-Immunotherapy Innovation and Research Unit (OITIRU) at Karolinska Institutet
Conducting clinical trials on immunotherapy treatments for cancer patients
Studying immune system responses in cancer patients undergoing immunotherapy
Personalized Cancer Treatment
A significant focus of his work is on developing personalized approaches to cancer therapy:
Creating algorithms to define more accurate prognoses and personalized treatment plans for cancer patients
Applying machine learning and AI to optimize cancer treatment strategies
Clinical Oncology
As a senior oncologist at Karolinska University Hospital, his research extends to clinical practice:
Planning and conducting over 30 clinical trials as principal investigator over the past 20 years
Specializing in oncology and radiotherapy
Tumor Immunology
His background in tumor immunology continues to inform his research:
Studying myeloid-derived suppressor cells (MDSC) in human malignancies
Investigating lymphocytic reactions in colon cancer prognosis
Translational Research
Professor Masucci is involved in translational research, bridging laboratory findings with clinical applications:
Coordinating networks like the "Nordic Centrum of Excellence for Tumours Vaccination" and "Scandinavian Network for Immunotherapy of Cancer (SNIC)"
Publishing extensively on topics ranging from basic immunology to clinical trial outcomes
Through these diverse but interconnected research areas, Professor Masucci contributes significantly to advancing cancer treatment and understanding the complex interactions between tumors and the immune system.

Articles

Article: CANCERS. 2023;15(2):418
Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer
Mlecnik B; Lugli A; Bindea G; Marliot F; Bifulco C; Lee J-KJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Borger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Grutzmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Leonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; Van Lent-van Vliet S; Knijn N; Musing A-M; Scripcariu D-V; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Patel P; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pages F; Galon J
Article: CANCERS. 2022;14(18):4346
Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study
Mlecnik B; Torigoe T; Bindea G; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Hirohashi Y; Furuhata T; Takemasa I; Patel P; Vora H; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Yoshino T; Taniguchi H; Bifulco C; Lugli A; Lee J-KJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Borger E; Hartmann A; Geppert CI; Kolwelter J; Merkel S; Gruetzmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Leonard D; Remue C; Wang J; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson E; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Marliot F; Fredriksen T; Buttard B; Lafontaine L; Maby P; Majdi A; Hijazi A; El Sissy C; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; Van de Water C; Van Lent-van Vliet S; Knijn N; Muaina A-M; Scripcariu D-V; Marincola FM; Ascierto PA; Fox BA; Pages F; Kawakami Y; Galon J
Article: CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 2022;36:91-98
Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases
Lindberg S; Onjukka E; Wersall P; Staff C; Lewensohn R; Masucci G; Lindberg K
Article: CANCERS. 2021;13(16):4164
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
Madonna G; Masucci GV; Capone M; Mallardo D; Grimaldi AM; Simeone E; Vanella V; Festino L; Palla M; Scarpato L; Tuffanelli M; D'angelo G; Villabona L; Krakowski I; Eriksson H; Simao F; Lewensohn R; Ascierto PA
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2021;19(1):132
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis
Isgro MA; Vitale MG; Celentano E; Nocerino F; Porciello G; Curvietto M; Mallardo D; Montagnese C; Russo L; Zanaletti N; Avallone A; Pensabene M; De Laurentiis M; Centonze S; Pignata S; Cannella L; Morabito A; Caponigro F; Botti G; Masucci GV; Giannarelli D; Cavalcanti E; Ascierto PA
Article: CANCERS. 2021;13(2):E265-265
Sex Differences in Overall Survival and the Effect of Radiotherapy in Merkel Cell Carcinoma-A Retrospective Analysis of A Swedish Cohort
Andtback HB; Bjornhagen-Safwenberg V; Shi H; Lui W-O; Masucci GV; Villabona L
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):105-115
Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting
Krakowski I; Bottai M; Habel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8(2):e001472
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges
Cesano A; Cannarile MA; Gnjatic S; Gomes B; Guinney J; Karanikas V; Karkada M; Kirkwood JM; Kotlan B; Masucci GV; Meeusen E; Monette A; Naing A; Thorsson V; Tschernia N; Wang E; Wells DK; Wyant TL; Rutella S
Article: CANCERS. 2020;12(11):E3238-3238
Prognostic Interactions between FAP plus Fibroblasts and CD8a+T Cells in Colon Cancer
Herrera M; Mezheyeuski A; Villabona L; Corvigno S; Strell C; Klein C; Holzlwimmer G; Glimelius B; Masucci G; Sjoblom T; Ostman A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(31):3638-3651
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer
Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Borger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Gruetzmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Leonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Musina A-M; Scripcariu D-V; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pages F; Galon J
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8(2):e001389
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges
Rutella S; Cannarile MA; Gnjatic S; Gomes B; Guinney J; Karanikas V; Karkada M; Kirkwood JM; Kotlan B; Masucci GV; Meeusen E; Monette A; Naing A; Thorsson V; Tschernia N; Wang E; Wells DK; Wyant TL; Cesano A
Article: ONCOIMMUNOLOGY. 2020;9(1):1786888
PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
de Coana YP; Wolodarski M; Avila IVDH; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Article: ONCOIMMUNOLOGY. 2020;9(1):1792058
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
Lovgren T; Wolodarski M; Wickstrom S; Edback U; Wallin M; Martell E; Markland K; Blomberg P; Nystrom M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15_suppl):e22063
Effectiveness of PD1-inhibitors in advanced Merkel cell carcinoma: Real life data in a Swedish cohort.
Bjorn-Andtback H; Masucci GV; Villabona LEE
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2019;17(1):234
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)
Ascierto PA; Agarwala SS; Botti G; Budillon A; Davies MA; Dummer R; Ernstoff M; Ferrone S; Formenti S; Gajewski TF; Garbe C; Hamid O; Lo RS; Luke JJ; Michielin O; Palmieri G; Zitvogel L; Marincola FM; Masucci G; Caraco C; Thurin M; Puzanov I
Article: MOLECULAR ONCOLOGY. 2019;13(2):376-391
Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer
Franzen B; Alexeyenko A; Kamali-Moghaddam M; Hatschek T; Kanter L; Ramqvist T; Kierkegaard J; Masucci G; Auer G; Landegren U; Lewensohn R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2018;16(1):207
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)
Ascierto PA; Puzanov I; Agarwala SS; Bifulco C; Botti G; Caraco C; Ciliberto G; Davies MA; Dummer R; Ferrone S; Gajewski TF; Garbe C; Luke JJ; Marincola FM; Masucci G; Mehnert JM; Mozzillo N; Palmieri G; Postow MA; Schoenberger SP; Wang E; Thurin M
Article: THE LANCET. 2018;391(10135):2128-2139
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Pages F; Mlecnik B; Marliot F; Bindea G; Ou F-S; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Borger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Gruetzmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Leonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Ina A-MM; Scripcariu D-V; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
Article: EUROPEAN JOURNAL OF CANCER. 2017;86:115-124
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
Petrella TM; Robert C; Richtig E; Miller WHJ; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2017;15(1):212
World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016
Galon J; Lugli A; Bifulco C; Pages F; Masucci G; Marincola FM; Ascierto PA
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2017;66(10):1333-1344
Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists
Lovgren T; Sarhan D; Truxova I; Choudhary B; Maas R; Melief J; Nystrom M; Edback U; Vermeij R; Scurti G; Nishimura M; Masucci G; Karlsson-Parra A; Lundqvist A; Adamson L; Kiessling R
Article: ONCOTARGET. 2017;8(13):21539-21553
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
de Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nystrom M; Edback U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Journal article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2016;4(Suppl 2):91
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
Althammer S; Steele K; Rebelatto M; Tan TH; Wiestler T; Schmidt G; Higgs B; Li X; Shi L; Jin X; Antal J; Gupta A; Ranade K; Binning G; Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Puhlmann M; Perini RF; Bajorin DF; Sharma P; Callahan MK; Calvo E; Kim JW; de Braud F; Ott PA; Bono P; Pillai RN; Morse M; Le DT; Taylor M; Spilliopoulou P; Bendell J; Jaeger D; Chan E; Antonia SJ; Ascierto PA; Hennicken D; Tschaika M; Azrilevich A; Rosenberg J; Levy O; Chan C; Cojocaru G; Liang S; Ophir E; Ganguly S; Toporik A; Kotturi M; Kfir TF; Murter BM; Logronio K; Dassa L; Leung L; Greenwald S; Azulay M; Kumar S; Alteber Z; Pan X; Machlenkin A; Benita Y; Drake AW; Chajut A; Salomon R; Vankin I; Safyon E; Hunter J; Levine Z; White M; Leidner R; Kang H; Haddad R; Segal NH; Wirth LJ; Ferris RL; Hodi FS; Sanborn RE; Gajewski TF; Sharfman W; McDonald D; Srivastava S; Gu X; Phillips P; Passey C; Seiwert T; Habtetsion T; Zhou G; Sakellariou-Thompson D; Haymaker C; Creasy C; Hurd M; Uraoka N; Canales JR; Koptez S; Hwu P; Maitra A; Bernatchez C; Coyle SM; Roybel KT; Rupp LJ; Santoro SP; Secrest S; Spelman M; Ho H; Gomes T; Tse T; Yung-Wu C; Taunton J; Lim W; Emtage P; Moudgil T; Ballesteros-Merino C; Hilton T; Paustian C; Leidner R; Page D; Urba W; Fox B; Bell B; Patel A; Olafsen T; Satpayev D; Torgov M; Marchioni F; Romero J; Jiang ZK; Zamilpa C; Keppler JS; Mascioni A; Jia F; Lee C-Y; Gudas J; Sullivan RJ; Hoshida Y; Logan T; Khushalani N; Giobbie-Hurder A; Margolin K; Roder J; Bhatt R; Koon H; Olencki T; Hutson T; Curti B; Blackmon S; Mier JW; Puzanov I; Roder H; Stewart J; Amin A; Ernstoff MS; Clark JI; Atkins MB; Kaufman HL; Sosman J; Signoretti S; McDermott DF; Anderson AA; Puzanov I; Milhem MM; Andtbacka RHI; Minor D; Gorski KS; Baker DM; Hamid O; Kaufman HL; Akporiaye E; Curti B; Koguchi Y; Leidner R; Sutcliffe K; Conder K; Urba W; Marron T; Bhardwaj N; Hammerich L; George F; Kim-Schulze S; Keler T; Davis T; Crowley E; Salazar A; Brody J; Monjazeb A; Daly ME; Riess J; Li T; Murphy WJ; Kelly K; Hu Z; Shen R; Campbell A; McMichael E; Yu L; Ramaswam B; London CA; Xu T; Carson W; Kokolus KM; Repasky EA; Schell TD; Drabick JD; Messenheimer DJ; Jensen S; Fox B; Rubinstein M; Andrijauskaite K; Swiderska-syn M; Lind K; Choppin A; Roell MK; Wrangle J; Andrijauskaite K; Swiderska-syn M; Rhode P; Wong H; Rubinstein M; Ahmad S; Webb M; Abu-Eid R; Shrimali R; Verma V; Doroodchi A; Berrong Z; Yashar D; Samara R; Mkrtichyan M; Khleif S; Powell S; Gitau M; Sumey C; Terrell A; Lohr M; Nowak RK; McGraw S; Jensen A; Blanchard M; Gold KA; Cohen EEW; Ellison C; Black L; Lee J; Spanos WC; Wennerberg E; Schwitzer E; Lhuillier C; Koelwyn G; Hiner R; Jones L; Demaria S; Amanda V; Greiner JW; Schlom J; Bookstaver M; Jewell CM; Paustian C; Gunderson A; Boulmay B; Li R; Spieler B; Happel K; Moudgil T; Feng Z; Ballesteros-Merino C; Dubay C; Fisher B; Koguchi Y; Aung S; Mederos E; Bifulco CB; McNamara M; Bahjat K; Redmond W; Ochoa A; Hu H-M; Mehta A; Lund-Johansen F; Fox B; Urba W; Sanborn RE; Hilton T; Bedu-Addo F; Conn G; King M; Dutta P; Shepard R; Einstein M; Adams S; Wang E; Jin P; Novik Y; Morrison D; Oratz R; Marincola FM; Stroncek D; Goldberg J; Demaria S; Formenti SC; Galon J; Mlecnik B; Marliot F; Ou F-S; Bifulco CB; Lugli A; Zlobec I; Rau TT; Nagtegaal ID; Vink-Borger E; Hartmann A; Geppert C; Roehrl MH; Bavi P; Ohashi PS; Wang JY; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Kawakami Y; Papivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Itoh K; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Torigoe T; Sato N; Furuhata T; Takemasa I; Van den Eynde M; Jouret-Mourin A; Machiels J-P; Fredriksen T; Lafontaine L; Buttard B; Church S; Maby P; Angell H; Angelova M; Vasaturo A; Bindea G; Berger A; Lagorce C; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Masucci GV; Andersson EK; Grizzi F; Laghi L; Botti G; Tatangelo F; Delrio P; Cilberto G; Ascierto PA; Marincola F; Sargent DJ; Fox BA; Algazi A; Tsai K; Rosenblum M; Nandoskar P; Andtbacka RHI; Li A; Nonomura J; Takamura K; Dwyer M; Browning E; Talia R; Twitty C; Gargosky S; Campbell J; Ballesteros-Merino C; Bifulco CB; Fox B; Le M; Pierce RH; Daud A; Gartrell R; Marks D; Stack E; Lu Y; Izaki D; Beck K; Jia DT; Armenta P; White-Stern A; Fu Y; Blake Z; Kaufman HL; Taback B; Horst B; Saenger YM; Leonardo S; Gorden K; Fulton RB; Fraser K; Kangas TO; Walsh R; Ertelt K; Graff J; Uhlik M; Sims JS; Lei L; Tsujiuchi T; Bruce JN; Canoll P; Tolcher AW; Alley EW; Chichili G; Canoll JE; Moore P; Bonvini E; Johnson S; Shankar S; Vasselli J; Wigginton J; Powderly J
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14(1):313
Future perspectives in melanoma research
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
Journal article: CANCER IMMUNOLOGY RESEARCH. 2016;4(11):b026
MDSCs and CD8 effector memory T cells correlate with survival in melanoma patients treated with ipilimumab
De Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Masucci G; Hansson J; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14:273
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
Galon J; Fox BA; Bifulco CB; Masucci G; Rau T; Botti G; Marincola FM; Ciliberto G; Pages F; Ascierto PA; Capone M
Journal article: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14(1):65
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
Nanda VGY; Peng W; Hwu P; Davies MA; Ciliberto G; Fattore L; Malpicci D; Aurisicchio L; Ascierto PA; Croce CM; Mancini R; Spranger S; Gajewski TF; Wang Y; Ferrone S; Vanpouille-Box C; Wennerberg E; Pilones KA; Formenti SC; Demaria S; Tang H; Wang Y; Fu Y-X; Dummer R; Puzanov I; Tarhini A; Chauvin J-M; Pagliano O; Fourcade J; Sun Z; Wang H; Sanders C; Kirkwood JM; Chen T-HT; Maurer M; Korman AJ; Zarour HM; Stroncek DF; Huber V; Rivoltini L; Thurin M; Rau T; Lugli A; Pagès F; Camarero J; Sancho A; Jommi C; de Coaña YP; Wolodarski M; Yoshimoto Y; Gentilcore G; Poschke I; Masucci GV; Hansson J; Kiessling R; Scognamiglio G; Sabbatino F; Marino FZ; Anniciello AM; Cantile M; Cerrone M; Scala S; D’alterio C; Ianaro A; Cirin G; Liguori G; Bott G; Chapman PB; Robert C; Larkin J; Haanen JB; Ribas A; Hogg D; Hamid O; Testori A; Lorigan P; Sosman JA; Flaherty KT; Yue H; Coleman S; Caro I; Hauschild A; McArthur GA; Sznol M; Callahan MK; Kluger H; Postow MA; Gordan R; Segal NH; Rizvi NA; Lesokhin A; Atkins MB; Burke MM; Ralabate A; Rivera A; Kronenberg SA; Agunwamba B; Ruisi M; Horak C; Jiang J; Wolchok J; Ascierto PA; Liszkay G; Maio M; Mandalà M; Demidov L; Stoyakovskiy D; Thomas L; de la Cruz-Merino L; Atkinson V; Dutriaux C; Garbe C; Wongchenko M; Chang I; Koralek DO; Rooney I; Yan Y; Dréno B; Sullivan R; Patel M; Hodi S; Amaria R; Boasberg P; Wallin J; He X; Cha E; Richie N; Ballinger M; Smith DC; Bauer TM; Wasser JS; Luke JJ; Balmanoukian AS; Kaufman DR; Zhao Y; Maleski J; Leopold L; Gangadhar TC; Long GV; Michielin O; VanderWalde A; Andtbacka RHI; Cebon J; Fernandez E; Malvehy J; Olszanski AJ; Gause C; Chen L; Chou J; Stephen Hodi F; Brady B; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Lebbé C; Ny L; Chacon M; Queirolo P; Loquai C; Cheema P; Berrocal A; Eizmendi KM; Bar-Sela G; Horak C; Hardy H; Weber JS; Grob J-J; Marquez-Rodas I; Schmidt H; Briscoe K; Baurain J-F; Wolchok JD; Pinto R; De Summa S; Garrisi VM; Strippoli S; Azzariti A; Guida G; Guida M; Tommasi S; Jacquelot N; Enot D; Flament C; Pitt JM; Vimond N; Blattner C; Yamazaki T; Roberti M-P; Vetizou M; Daillere R; Poirier-Colame V; la Semeraro M; Caignard A; Slingluff CL; Sallusto F; Rusakiewicz S; Weide B; Marabelle A; Kohrt H; Dalle S; Cavalcanti A; Kroemer G; Di Giacomo AM; Maio M; Wong P; Yuan J; Umansky V; Eggermont A; Zitvogel L; Anna P; Marco T; Stefania S; Francesco M; Mariaelena C; Gabriele M; Antonio AP; Franco S; Roberti MP; Enot DP; Semeraro M; Jégou S; Flores C; Chen T-HT; Kwon BS; Anderson AC; Borg C; Aubin F; Ayyoub M; De Presbiteris AL; Cordaro FG; Camerlingo R; Fratangelo F; Mozzillo N; Pirozzi G; Patriarca EJ; Caputo E; Motti ML; Falcon R; Miceli R; Capone M; Madonna G; Mallardo D; Carrier MV; Panza E; De Cicco P; Armogida C; Ercolano G; Botti G; Cirino G; Sandru A; Blank M; Balatoni T; Olasz J; Farkas E; Szollar A; Savolt A; Godeny M; Csuka O; Horvath S; Eles K; Shoenfeld Y; Kasler M; Costantini S; Capone F; Moradi F; Berglund P; Leandersson K; Linnskog R; Andersson T; Prasad CP; Nigro CL; Lattanzio L; Wang H; Proby C; Syed N; Occelli M; Cauchi C; Merlano M; Harwood C; Thompson A; Crook T; Bifulco K; Ingangi V; Minopoli M; Ragone C; Pessi A; Mannavola F; D’Oronzo S; Felici C; Tucci M; Doronzo A; Silvestris F; Ferretta A; Guida S; Maida I; Cocco T; Passarelli A; Quaresmini D; Franzese O; Palermo B; Di Donna C; Sperduti I; Foddai M; Stabile H; Gismondi A; Santoni A; Nisticò P; Sponghini AP; Platini F; Marra E; Rondonotti D; Alabiso O; Fierro MT; Savoia P; Stratica F; Quaglino P; Di Monta G; Corrado C; Di Marzo M; Ugo M; Di Cecilia ML; Nicola M; Fusciello C; Marra A; Guarrasi R; Baldi C; Russo R; Di Giulio G; Faiola V; Zeppa P; Pepe S; Gambale E; Carella C; Di Paolo A; De Tursi M; Marra L; De Murtas F; Sorrentino V; Voinea S; Panaitescu E; Bolovan M; Stanciu A; Cinca S; Botti C; Aquino G; Anniciello A; Fortes C; Mastroeni S; Caggiati A; Passarelli F; Zappalà A; Capuano M; Bono R; Nudo M; Marino C; Michelozzi P; De Biasio V; Battarra VC; Formenti S; Ascierto ML; McMiller TL; Berger AE; Danilova L; Anders RA; Netto GJ; Xu H; Pritchard TS; Fan J; Cheadle C; Cope L; Drake CG; Pardoll DM; Taube JM; Topalian SL; Gnjatic S; Nataraj S; Imai N; Rahman A; Jungbluth AA; Pan L; Venhaus R; Park A; Lehmann FF; Lendvai N; Cohen AD; Cho HJ; Daniel S; Hirsh V
Article: ONCOIMMUNOLOGY. 2016;5(1):e1052213
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis
Andersson E; Poschke I; Villabona L; Carlson JW; Lundqvist A; Kiessling R; Seliger B; Masucci GV
Journal article: JOURNAL OF TRANSLATIONAL MEDICINE. 2015;13(Suppl 1):o7
Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
Pico de Coaña Y; Wolodarski M; Gentilcore G; Yoshimoto Y; Poschke I; Hansson J; Masucci GV; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2015;13:374
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Mc Arthur G; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
Article: TRANSLATIONAL RESEARCH. 2015;166(2):207-217
Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome
Koelzer VH; Dawson H; Andersson E; Karamitopoulou E; Masucci GV; Lugli A; Zlobec I
Journal article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2014;2(Suppl 3):p231
Ipilimumab treatment enhances CD4+ T cell activation while decreasing Treg and MDSC frequency in advanced melanoma patients
Pico de Coaña Y; Poschke I; Yoshimoto Y; Karlberg S; Nyström M; Wolodarski M; Hansson J; Masucci G; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2014;12:277
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Ascierto PA; Grimaldi AM; Anderson AC; Bifulco C; Cochran A; Garbe C; Eggermont AM; Faries M; Ferrone S; Gershenwald JE; Gajewski TF; Halaban R; Hodi FS; Kefford R; Kirkwood JM; Larkin J; Leachman S; Maio M; Marais R; Masucci G; Melero I; Palmieri G; Puzanov I; Ribas A; Saenger Y; Schilling B; Seliger B; Stroncek D; Sullivan R; Testori A; Wang E; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2014;63(10):1061-1071
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma
Poschke I; Lovgren T; Adamson L; Nystrom M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R
Article: MODERN PATHOLOGY. 2014;27(9):1296-1305
A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA
Villabona L; Leon Rodriguez DA; Andersson EK; Seliger B; Dalianis T; Masucci GV
Article: ANTICANCER RESEARCH. 2014;34(5):2369-2375
HLA-A*02 in Relation to Outcome in Human Papillomavirus Positive Tonsillar and Base of Tongue Cancer
Tertipis N; Villabona L; Nordfors C; Nasman A; Ramqvist T; Vlastos A; Masucci G; Dalianis T
Article: METHODS IN MOLECULAR BIOLOGY. 2014;1102:353-366
Genotyping of human leukocyte antigen (HLA) ancestral haplotypes as prognostic marker in cancer using PCR analysis.
Villabona L; Andersson E; Marchesi M; Masucci GV
Journal article: JOURNAL OF TRANSLATIONAL MEDICINE. 2014;12(Suppl 1):o9
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase 1 production
Gentilcore G; Pico de Yago C; Poschke I; Mao Y; Nyström M; Hansson J; Masucci GV; Kiessling R
Article: CANCER IMMUNOLOGY RESEARCH. 2013;1(3):158-162
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
de Coana YP; Poschke I; Gentilcore G; Mao Y; Nystrom M; Hansson J; Masucci GV; Kiessling R
Article: CANCER RESEARCH. 2013;73(13):3877-3887
Melanoma-Educated CD14⁺ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Mao Y; Poschke I; Wennerberg E; de Coana YP; Brage SE; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: INTERNATIONAL JOURNAL OF CANCER. 2013;132(1):72-81
MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome
Nasman A; Andersson E; Nordfors C; Grun N; Johansson H; Munck-Wikland E; Massucci G; Dalianis T; Ramqvist T
Article: PLOS ONE. 2013;8(10):e77025
HLA Class I and II Expression in Oropharyngeal Squamous Cell Carcinoma in Relation to Tumor HPV Status and Clinical Outcome
Nasman A; Andersson E; Marklund L; Tertipis N; Hammarstedt-Nordenvall L; Attner P; Nyberg T; Masucci GV; Munck-Wikland E; Ramqvist T; Dalianis T
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(8):1243-1253
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer
Andersson E; Villabona L; Bergfeldt K; Carlson JW; Ferrone S; Kiessling R; Seliger B; Masucci GV
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(6):827-838
Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines
Poschke I; Mao Y; Adamson L; Salazar-Onfray F; Masucci G; Kiessling R
Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2011;9:214
Defining the critical hurdles in cancer immunotherapy
Fox BA; Schendel DJ; Butterfield LH; Aamdal S; Allison JP; Ascierto PA; Atkins MB; Bartunkova J; Bergmann L; Berinstein N; Bonorino CC; Borden E; Bramson JL; Britten CM; Cao X; Carson WE; Chang AE; Characiejus D; Choudhury AR; Coukos G; de Gruijl T; Dillman RO; Dolstra H; Dranoff G; Durrant LG; Finke JH; Galon J; Gollob JA; Gouttefangeas C; Grizzi F; Guida M; Hakansson L; Hege K; Herberman RB; Hodi FS; Hoos A; Huber C; Hwu P; Imai K; Jaffee EM; Janetzki S; June CH; Kalinsk P; Kaufman HL; Kawakami K; Kawakami Y; Keilholtz U; Khleif SN; Kiessling R; Kotlan B; Kroemer G; Lapointe R; Levitsky HI; Lotze MT; Maccalli C; Maio M; Marschner J-P; Mastrangelo MJ; Masucci G; Melero I; Melief C; Murphy WJ; Nelson B; Nicolini A; Nishimura MI; Odunsi K; Ohashi PS; O'Donnell-Tormey J; Old LJ; Ottensmeier C; Papamichail M; Parmiani G; Pawelec G; Proietti E; Qin S; Rees R; Ribas A; Ridolfi R; Ritter G; Rivoltini L; Romero PJ; Salem ML; Scheper RJ; Seliger B; Sharma P; Shiku H; Singh-Jasuja H; Song W; Straten PT; Tahara H; Tian Z; van Der Burg SH; von Hoegen P; Wang E; Welters MJP; Winter H; Withington T; Wolchok JD; Xiao W; Zitvogel L; Zwierzina H; Marincola FM; Gajewski TF; Wigginton JM; Disis ML
Article: LAKARTIDNINGEN. 2011;108(20):1092-1093
[Paradigmatic shift in oncology: individualized melanoma treatment].
Hansson J; Djureen-Mårtenson E; Edvinsson F; Falkenius J; Friesland S; Masucci G; Månsson-Brahme E; Ragnarsson-Olding B; Sjödin H; Wolodarski M; Frohm-Nilsson M; Lapins J
Article: CLINICAL CANCER RESEARCH. 2011;17(10):3064-3076
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
Butterfield LH; Palucka AK; Britten CM; Dhodapkar MV; Hakansson L; Janetzki S; Kawakami Y; Kleen T-O; Lee PP; Maccalli C; Maecker HT; Maino VC; Maio M; Malyguine A; Masucci G; Pawelec G; Potter DM; Rivoltini L; Salazar LG; Schendel DJ; Slingluff CLJ; Song W; Stroncek DF; Tahara H; Thurin M; Trinchieri G; van Der Burg SH; Whiteside TL; Wigginton JM; Marincola F; Khleif S; Fox BA; Disis ML
Article: PHARMACEUTICAL STATISTICS. 2011;10(3):218-226
Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas
Zohar S; Baldi I; Forni G; Merletti F; Masucci G; Gregori D
Article: CANCER RESEARCH. 2010;70(11):4335-4345
Immature Immunosuppressive CD14⁺HLA-DR^-/low Cells in Melanoma Patients Are Stat3^hi and Overexpress CD80, CD83, and DC-Sign
Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
Journal article: JOURNAL OF NUCLEIC ACIDS INVESTIGATION. 2010;1(1):9
Survival of the fittest or best adapted: HLA-dependent tumor development
Masucci GV; Andersson E; Villabona L; Helgadottir H; Bergfeldt K; Cavallo F; Forni G; Ferrone S; Choudhury A; Seliger B; Kiessling R
Article: CANCER RESEARCH. 2010;70(7):2604-2612
A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
Quaglino E; Mastini C; Amici A; Marchini C; Iezzi M; Lanzardo S; De Giovanni C; Montani M; Lollini P-L; Masucci G; Forni G; Cavallo F
Journal article: JOURNAL OF NUCLEIC ACIDS INVESTIGATION. 2010;1(1):9
Survival of the fittest or best adapted: HLA-dependent tumor development
Masucci GV; Andersson E; Villabona L; Helgadottir H; Bergfeldt K; Cavallo F; Forni G; Ferrone S; Choudhury A; Seliger B; Kiessling R
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2009;58(10):1599-1608
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma
Helgadottir H; Andersson E; Villabona L; Kanter L; van der Zanden H; Haasnoot GW; Seliger B; Bergfeldt K; Hansson J; Ragnarsson-Olding B; Kiessling R; Masucci GV
Journal article: CELL BIOLOGY INTERNATIONAL. 2009;33(8):816-829
Tissue-specific expression of dentin sialophosphoprotein (DSPP) and its polymorphisms in mouse tissues
Yuan G; Wang Y; Gluhak-Heinrich J; Yang G; Chen L; Li T; Wu L-A; Chen Z; MacDougall M; Chen S
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2009;58(7):1085-1094
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
Johansson CC; Egyhazi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Article: HLA. 2007;70(3):205-213
Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer
Gamzatova Z; Villabona L; van der Zanden H; Haasnoot GW; Andersson E; Kiessling R; Seliger B; Kanter L; Dalianis T; Bergfeldt K; Masucci GV
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2007;56(7):973-984
A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
Hanson MGV; Ozenci V; Carlsten MCV; Glimelius BL; Frodin J-EA; Masucci G; Malmberg K-J; Kiessling RVR
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(18_suppl):21059
Lack of p21/Waf-1 expression and lymphocyte infiltration in primary ovarian cancer correlate with the somatic HLA-A2 expression
Andersson E; Villabona L; Kanter L; Gamzatova Z; Kiessling R; Dalianis T; Bergfeldt K; Masucci GV
Article: GYNECOLOGIC ONCOLOGY. 2006;103(1):145-150
Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer
Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Nillson B; Bergfeldt K; Masucci GV
Article: MELANOMA RESEARCH. 2006;16(4):357-363
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma
Masucci GV; Mansson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2006;24(18_suppl):14543
High frequency of human leucocyte antigen (HLA) A2 and HLA-B7, -B44, -B15 and -DRB1–4 haplotypes in Swedish prostate cancer patients
Masucci GV; Andersson E; Egevad L; Kälkner K; Harmenberg U; Ryberg M; Nilsson S; Pisa P
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2006;24(18_suppl):20100
Swedish ovarian cancer patients are found with a high frequency of human leucocyte antigen (HLA) A2, -B7, -B12, -B15 -B44 and -DRB1–4 haplotypes
Bergfeldt K; Gamzatova Z; Tholander B; Bergdahl M; Nordström B; Hjerpe E; Masucci G
Article: CANCER RESEARCH. 2006;66(12):6387-6394
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity
Norell H; Carlsten M; Ohlum T; Malmberg K-J; Masucci G; Schedvins K; Altermann W; Handke D; Atkins D; Seliger B; Kiessling R
Article: IMMUNOLOGY LETTERS. 2005;100(2):113-119
Effects of human plasma proteins on maturation of monocyte-derived dendritic cells
Tobiásová-Czetoová Z; Palmborg A; Lundqvist A; Karlsson G; Adamson L; Bartunková J; Masucci G; Pisa P
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16_suppl):5096
Human leucocyte antigen (HLA) A2 phenotype incidence in patients with advanced ovarian cancer as negative clinical prognostic factor
Masucci GV; Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Åvall-Lundqvist E; Bergfeldt K
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16_suppl):5054
High frequency of human leucocyte antigen (HLA) A2 reflects a poorer prognosis in a group of advanced ovarian cancer patients
Bergfeldt K; Hising C; Gamzatova Z; Tholander B; Åvall-Lundqvist E; van der Zanden HGM; Masucci G
Article: MEDICAL ONCOLOGY. 2005;22(3):247-256
Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy -: A multicenter open randomized phase III study
Masucci G; Broman P; Kelly C; Lindahl S; Malmberg L; Reizenstein J; Ålenius M; Lewensohn R
Journal article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2004;14(Suppl 1):52.2-5252
ASSOCIATION BETWEEN EXPRESSION OF HLA-A2 AND OVARIAN CANCER
Bergfeldt K; Gamzatova Z; de Petris L; Tholander B; Hising C; Alm C; Bergdahl M; Nordstrom B; van der Zanden HGM; Masucci G
Article: BRITISH JOURNAL OF CANCER. 2004;91(4):688-694
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer
Pavlenko M; Roos AK; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(14_suppl):7541
Alternating temozolomide and low doses rIL-2 in patients with metastatic melanoma. An open non-randomized phase I/II study
Masucci GV; Djuren-Mårtensson E; Hansson J; Månsson-Brahme E; Ragnarsson-Olding B; Wagenius G
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(14_suppl):7541
Alternating temozolomide and low doses rIL-2 in patients with metastatic melanoma. An open non-randomized phase I/II study
Masucci GV; Djuren-Mårtensson E; Hansson J; Månsson-Brahme E; Ragnarsson-Olding B; Wagenius G
Article: MEDICAL ONCOLOGY. 2004;21(1):49-52
Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates
De Petris L; Bergfeldt K; Hising C; Lundqvist A; Tholander B; Pisa P; van der Zanden HGM; Masucci G
Article: CYTOTHERAPY. 2004;6(4):363-371
Development of a technology platform for large-scale clinical grade production of DC
Adamson L; Palmborg A; Svensson A; Lundqvist A; Hansson M; Kiessling R; Masucci G; Mellstedt H; Pisa P
Article: CLINICAL CANCER RESEARCH. 2002;8(6):1772-1778
A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer
Malmberg KJ; Lenkei R; Petersson M; Ohlum T; Ichihara F; Glimelius B; Frödin JE; Masucci G; Kiessling R
Article: HEAD AND NECK. 2001;23(11):1006-1010
Leakage around voice prosthesis in laryngectomees:: Treatment with local GM-CSF
Margolin G; Masucci G; Kuylenstierna R; Björck G; Hertegård S; Karling J
Journal article: EUROPEAN JOURNAL OF CANCER. 2001;37:s19
Specific vaccination based on the Her2/neu proto-oncogene
Kiessling R; Lindencrona J-A; Charo J; Hising C; Masucci G; Petersson M; Bergh J; Franksson L
Article: JOURNAL OF IMMUNOLOGY. 2001;167(5):2595-2601
Inhibition of activated/memory (CD45RO⁺) T cells by oxidative stress associated with block of NF-κB activation
Malmberg KJ; Arulampalam V; Ichihara F; Petersson M; Seki K; Andersson T; Lenkei R; Masucci G; Pettersson S; Kiessling R
Article: MEDICAL ONCOLOGY. 2001;18(3):231-235
GM-CSF at relatively high topic concentrations can significantly enhance the healing of surgically induced chronic wounds after radiotherapy
Fernberg JO; Brosjö O; Friesland S; Masucci G
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;80(2):219-230
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
Marchand M; van Baren N; Weynants P; Brichard V; Dréno B; Tessier MH; Rankin E; Parmiani G; Arienti F; Humblet Y; Bourlond A; Vanwijck R; Liénard D; Beauduin M; Dietrich PY; Russo V; Kerger J; Masucci G; Jäger E; De Greve J; Atzpodien J; Brasseur F; Coulie PG; Van der Bruggen P; Boon T
Article: CANCER RESEARCH. 1997;57(19):4348-4355
Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells
SalazarOnfray F; Nakazawa T; Chhajlani V; Petersson M; Karre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
Article: STEM CELLS AND DEVELOPMENT. 1997;6(3):253-260
Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis)
Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
Article: MEDICAL ONCOLOGY. 1996;13(3):149-154
New clinical applications of granulocyte-macrophage colony-stimulating factor
Masucci G
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1996;26(6):1308-1313
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity
Kono K; SalazarOnfray F; Petersson M; Hansson J; Masucci G; Wasserman K; Nakazawa T; Anderson P; Kiessling R
Article: CANCER RESEARCH, THERAPY AND CONTROL. 1995;4(3):223-229
ANTIBODIES TO EPSTEIN-BARR-VIRUS IN RELATION TO CLINICAL CHARACTERISTICS OF UNTREATED PATIENTS WITH HODGKINS-DISEASE
MERK K; LENNETTE E; HOLM G; JOHANSSON B; MASUCCI G; GRIMFORS G; KLEIN G; BJORKHOLM M
Journal article: JOURNAL OF EXPERIMENTAL MEDICINE (JEM). 1994;180(6):2371-2376
INTERLEUKIN-10 PRETREATMENT PROTECTS TARGET-CELLS FROM TUMOR-SPECIFIC AND ALLO-SPECIFIC CYTOTOXIC T-CELLS AND DOWN-REGULATES HLA CLASS-I EXPRESSION
MATSUDA M; SALAZAR F; PETERSSON M; MASUCCI G; HANSSON J; PISA P; ZHANG QJ; MASUCCI MG; KIESSLING R
Journal article: CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY. 1994;71(1):105-112
INTERFERON-GAMMA ENHANCES MONOCLONAL-ANTIBODY 17-1A-DEPENDENT NEUTROPHIL CYTOTOXICITY TOWARD COLORECTAL-CARCINOMA CELL-LINE SW11-16
REALI E; GUILIANI AL; SPISANI S; MORETTI S; GAVIOLI R; MASUCCI G; GAMBARI R; TRANIELLO S
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1993;53(5):751-758
EFFECT OF MONOCLONAL-ANTIBODY 17-1A AND GM-CSF IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA - LONG-LASTING, COMPLETE REMISSIONS CAN BE INDUCED
RAGNHAMMAR P; FAGERBERG J; FRODIN JE; HJELM AL; LINDEMALM C; MAGNUSSON I; MASUCCI G; MELLSTEDT H
Journal article: CANCER JOURNAL. 1993;6(3):116-122
GM-CSF AUGMENTS THE IL-4-INDUCED CYTOTOXIC ACTIVITY OF HUMAN MONONUCLEAR-CELLS IN THE PRESENCE OF THE MOUSE MONOCLONAL-ANTIBODY 17-1A
REALI E; MELLSTEDT H; MASUCCI G
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1993;10(1-2):61-70
THE THERAPEUTIC USE OF THE UNCONJUGATED MONOCLONAL-ANTIBODIES (MAB) 17-1A IN COMBINATION WITH GM-CSF IN THE TREATMENT OF COLORECTAL-CARCINOMA (CRC)
RAGNHAMMAR P; MAGNUSSON I; MASUCCI G; MELLSTEDT H
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1993;10(3):103-111
LOW-DOSE CYCLOPHOSPHAMIDE, ALPHA-INTERFERON AND CONTINUOUS INFUSIONS OF INTERLEUKIN-2 IN ADVANCED RENAL-CELL CARCINOMA
WERSALL JP; MASUCCI G; HJELM AL; RAGNHAMMAR P; FAGERBERG J; FRODIN JE; MERK K; LINDEMALM C; ERICSON K; KALIN B; MELLSTEDT H
Journal article: EUROPEAN JOURNAL OF CANCER. 1993;29A(11):1584-1589
DISEASE-RELATED DIFFERENCES IN ANTIBODY PATTERNS AGAINST EBV-ENCODED NUCLEAR ANTIGENS EBNA-1, EBNA-2 AND EBNA-6
LENNETTE ET; RYMO L; YADAV M; MASUCCI G; MERK K; TIMAR L; KLEIN G
Journal article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1993;36(3):191-197
RESTRICTED T-CELL RECEPTOR V-BETA AND J-BETA USAGE IN T-CELLS FROM INTERLEUKIN-2-CULTURED LYMPHOCYTES OF OVARIAN AND RENAL CARCINOMAS
HALAPI E; YAMAMOTO Y; JUHLIN C; JEDDITEHRANI M; GRUNEWALD J; ANDERSSON R; HISING C; MASUCCI G; MELLSTEDT H; KIESSLING R
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1992;9(1):25-33
DIVERSE EFFECT OF CYTOKINE TREATMENT OF TUMOR-CELLS ON SPECIFIC VERSUS NONSPECIFIC CYTOTOXICITY
NAGANUMA H; HALAPI E; MASUCCI G; HANSSON M; WERSALL P; HISING C; VENKATESWARAN S; MELLSTEDT H; KIESSLING R
Journal article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1992;35(3):158-164
CYTOTOXIC FUNCTIONS OF BLOOD MONONUCLEAR-CELLS IN PATIENTS WITH COLORECTAL-CARCINOMA TREATED WITH MAB 17-1A AND GRANULOCYTE MACROPHAGE-COLONY-STIMULATING FACTOR
RAGNHAMMAR P; MASUCCI G; FRODIN JE; HJELM AL; MELLSTEDT H
Journal article: SEMINARS IN ONCOLOGY. 1991;18(5):462-477
THE THERAPEUTIC USE OF MONOCLONAL-ANTIBODIES IN COLORECTAL-CARCINOMA
MELLSTEDT H; FRODIN JE; MASUCCI G; RAGNHAMMAR P; FAGERBERG J; HJELM AL; SHETYE J; WERSALL P; OSTERBORG A
Journal article: HYBRIDOMA. 1991;10(4):421-431
INDUCTION OF ANTIIDIOTYPIC (AB2) AND ANTI-ANTI-IDIOTYPIC (AB3) ANTIBODIES IN PATIENTS TREATED WITH THE MOUSE MONOCLONAL-ANTIBODY 17-1A (AB1) - RELATION TO THE CLINICAL OUTCOME - AN IMPORTANT ANTITUMORAL EFFECTOR FUNCTION
FRODIN JE; FAXAS ME; HAGSTROM B; LEFVERT AK; MASUCCI G; NILSSON B; STEINITZ M; UNGER P; MELLSTEDT H
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1991;48(3):344-349
PATIENTS TREATED WITH A MONOCLONAL-ANTIBODY (AB1) TO THE COLORECTAL-CARCINOMA ANTIGEN-17-1A DEVELOP A CELLULAR-RESPONSE (DTH) TO THE INTERNAL IMAGE OF THE ANTIGEN (AB2)
MELLSTEDT H; FRODIN JE; BIBERFELD P; FAGERBERG J; GISCOMBE R; HERNANDEZ A; MASUCCI G; LI SL; STEINITZ M
Journal article: CANCER JOURNAL. 1991;4(3):168-173
COMBINATIONS OF IL-2, GM-CSF, IL-4, IFN-ALPHA AND TNF-ALPHA INCREASE THE ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) OF BLOOD MONONUCLEAR-CELLS IN PRESENCE OF EITHER MOUSE OR CHIMERIC MAB 17-1A - A PRECLINICAL EVALUATION
MASUCCI G; MELLSTEDT H
Journal article: LEUKEMIA RESEARCH. 1991;15(10):963
New aspects in the diagnosis and treatment of Hodgkin's disease In recent results in cancer research, edited by Diehl V., Pfreundschuh M. & Löffler M. (Springer, Berlin, 1990)
Masucci G
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1991;8(3):207-220
CHEMOTHERAPY AND IMMUNOTHERAPY OF COLORECTAL-CANCER
MASUCCI G; RAGNHAMMAR P; FRODIN JE; HJELM AL; WERSALL P; FAGERBERG J; OSTERBORG A; MELLSTEDT H
Journal article: ACTA ONCOLOGICA. 1991;30(8):923-931
THERAPY OF COLORECTAL-CARCINOMA WITH MONOCLONAL-ANTIBODIES (MAB17-1A) ALONE AND IN COMBINATION WITH GRANULOCYTE MONOCYTE-COLONY STIMULATING FACTOR (GM-CSF)
MELLSTEDT H; FRODIN JE; RAGNHAMMAR P; MASUCCI G; LJUNGBERG A; HJELM AL; FAGERBERG J; LINDEMALM C; OSTERBORG A; WERSALL P; CHRISTENSSON B; SHETYE J; BIBERFELD P; MAKOWER J; CEDERMARK B; ERWALD R; NATHANSSON J; MAGNUSSON I; RIEGER A
Journal article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1991;33(1):45-49
INTERLEUKIN-4 AUGMENTS THE CYTOTOXIC CAPACITY OF LYMPHOCYTES AND MONOCYTES IN ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
WERSALL P; MASUCCI G; MELLSTEDT H
Journal article: LEUKEMIA. 1990;4(2):81-82
BIOLOGIC THERAPEUTICS AS THE 4TH MODALITY IN CANCER-TREATMENT
MASUCCI G; MELLSTEDT H
Journal article: ACTA ONCOLOGICA. 1990;29(4):431-437
GENERATION OF HUMAN LAK CELLS IN TISSUE-CULTURE BAGS USING RECOMBINANT IL-2 AND SERUM FREE MEDIUM - EFFECTS OF PRETREATMENT WITH PHENYLALANINE-METHYLESTER
WERSALL P; MASUCCI G; PIHLSTEDT P; COTGREAVE I; TRIBUKAIT B; ULLBERG M; WIGZELL H; MELLSTEDT H
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1990;7(4):257-263
SIMPLIFIED LONG-TERM LARGE-SCALE PRODUCTION OF HIGHLY-ACTIVE HUMAN LAK CELLS FOR THERAPY
WERSALL P; MASUCCI G; PIHLSTEDT P; WIGZELL H; MELLSTEDT H
Journal article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1990;31(4):231-235
GRANULOCYTE-MONOCYTE COLONY-STIMULATING-FACTOR AUGMENTS THE INTERLEUKIN-2-INDUCED CYTOTOXIC ACTIVITY OF HUMAN-LYMPHOCYTES IN THE ABSENCE AND PRESENCE OF MOUSE OR CHIMERIC MONOCLONAL-ANTIBODIES (MAB 17-1A)
MASUCCI G; RAGNHAMMAR P; WERSALL P; MELLSTEDT H
Journal article: ONCOLOGY. 1989;3(12):25-32
Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma.
Mellstedt H; Frodin JE; Masucci G
Journal article: HYBRIDOMA. 1989;8(5):507-516
LYMPHOKINE ACTIVATED KILLER (LAK) CELLS IN ANTIBODY DEPENDENT CELLULAR CYTO-TOXICITY (ADCC) USING MAB 17-1A - A COMBINATION OF POTENTIAL USEFULNESS IN TUMOR-THERAPY
MASUCCI G; WERSALL P; NIELSEN J; NIELSEN HK; WIGZELL H; MELLSTEDT H
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1989;43(6):1017-1021
RELATIONSHIP BETWEEN CLINICAL STAGE, HISTOPATHOLOGY AND ANTIBODY-TITERS AGAINST THE 2ND EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN (EBNA-2) IN NON-HODGKINS LYMPHOMA PATIENTS
MASUCCI G; MELLSTEDT H; HENLE G; HENLE W; RYMO L; MASUCCI MG; ERNBERG I; KLEIN G
Journal article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 1989;24(3):257-268
BIOLOGIC RESPONSE MODIFIERS IN THE TREATMENT OF GASTROINTESTINAL MALIGNANCIES
MELLSTEDT H; FRODIN JE; LINDEMALM C; MASUCCI G; MERK K; PETTERSSON D; RAGNHAMMAR P; STEINITZ M; WEDELIN C; WERSALL P; OSTERBORG A
Journal article: ACTA CHIRURGICA SCANDINAVICA, SUPPLEMENT. 1989;549:63-70
MONOCLONAL-ANTIBODIES (MAB 17-1A) FOR THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CARCINOMAS
MELLSTEDT H; FRODIN JE; MASUCCI G; LINDEMALM C; WEDELIN C; CHRISTENSSON B; SHETYE J; BIBERFELD P; LEFVERT AK; PIHLSTEDT P; MAKOWER J
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1989;6(1):99-107
THE CLINICAL USE OF MONOCLONAL-ANTIBODIES, MAB 17-1A, IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA
MELLSTEDT H; FRODIN JE; RAGNHAMMAR P; MASUCCI G; SHETYE J; CHRISTENSSON B; BIBERFELD P; MAKOWER J; PIHLSTEDT P; CEDERMARK B; HARMENBERG U; WAHREN B; RIEGER A; MAGNUSSON I; NATHANSSON J; ERWALD R
Journal article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1989;29(4):288-292
GRANULOCYTE-MONOCYTE-COLONY-STIMULATING FACTOR AUGMENTS THE CYTO-TOXIC CAPACITY OF LYMPHOCYTES AND MONOCYTES IN ANTIBODY-DEPENDENT CELLULAR CYTO-TOXICITY
MASUCCI G; WERSALL P; RAGNHAMMAR P; MELLSTEDT H
Journal article: HYBRIDOMA. 1988;7(5):429-440
EFFECT OF HUMAN-BLOOD MONONUCLEAR CELL-POPULATIONS IN ANTIBODY DEPENDENT CELLULAR CYTO-TOXICITY (ADCC) USING 2 MURINE (CO17-1A AND BR55-2) AND ONE CHIMERIC (17-1A) MONOCLONAL-ANTIBODIES AGAINST A HUMAN COLORECTAL-CARCINOMA CELL-LINE (SW948)
MASUCCI G; LINDEMALM C; FRODIN JE; HAGSTROM B; MELLSTEDT H
Journal article: EUROPEAN JOURNAL OF CANCER AND CLINICAL ONCOLOGY. 1987;23(4):379-386
ANALYSIS OF EPSTEIN-BARR VIRUS-SPECIFIC AND NONSPECIFIC IMMUNE FUNCTIONS IN A PATIENT DURING THE DEVELOPMENT OF A NON-HODGKINS-LYMPHOMA
MASUCCI G; MELLSTEDT H; MASUCCI MG; ERNBERG I; SZIGETI R; HENLE G; HENLE W; KLEIN G
Journal article: IMMUNOLOGY LETTERS. 1985;9(5):267-273
LEUKOCYTE MIGRATION-INHIBITORY FACTOR PRODUCTION BY ACTIVATED LYMPHOCYTES REPRESENTING IMMUNOLOGICAL MEMORY OR VIRUS-RECEPTOR INTERACTION - RESPONSE OF T-CELL SUBSETS TO EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN, RESPONSE OF B-CELLS TO UV INACTIVATED EPSTEIN-BARR VIRUS
SZIGETI R; MASUCCI MG; MASUCCI G; AMAN P; KLEIN G; KLEIN E
Journal article: JOURNAL OF CLINICAL IMMUNOLOGY. 1984;4(5):369-382
EPSTEIN-BARR VIRUS (EBV)-SPECIFIC CELL-MEDIATED AND HUMORAL IMMUNE-RESPONSES IN ATAXIA-TELANGIECTASIA PATIENTS
MASUCCI G; BERKEL I; MASUCCI MG; ERNBERG I; SZIGETI R; ERSOY F; SANAL O; YEGIN O; HENLE G; HENLE W; PEARSON G; AMAN P; KLEIN G
Journal article: CELLULAR IMMUNOLOGY. 1984;85(2):511-518
PRODUCTION OF LEUKOCYTE MIGRATION-INHIBITORY FACTOR (LIF) IN HUMAN-LYMPHOCYTE SUBSETS EXPOSED TO POLYCLONAL ACTIVATORS
MASUCCI G; SZIGETI R; STEVENS D; MASUCCI MG; KLEIN E; PETERSEN J; BENDTZEN K; KLEIN G
Journal article: CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY. 1984;30(3):437-450
VIROLOGIC, IMMUNOLOGICAL, AND CLINICAL OBSERVATIONS ON A PATIENT DURING THE INCUBATION, ACUTE, AND CONVALESCENT PHASES OF INFECTIOUS MONONUCLEOSIS
SVEDMYR E; ERNBERG I; SEELEY J; WEILAND O; MASUCCI G; TSUKUDA K; SZIGETI R; MASUCCI MG; BLOMGREN H; BERTHOLD W; HENLE W; KLEIN G
Journal article: CANCER RESEARCH. 1984;44(3):1288-1300
IMMUNOLOGICAL CHARACTERIZATION OF HODGKINS AND NON-HODGKINS LYMPHOMA PATIENTS WITH HIGH ANTIBODY-TITERS AGAINST EPSTEIN-BARR VIRUS-ASSOCIATED ANTIGENS
MASUCCI G; MELLSTEDT H; MASUCCI MG; SZIGETI R; ERNBERG I; BJORKHOLM M; TSUKUDA K; HENLE G; HENLE W; PEARSON G; HOLM G; BIBERFELD P; JOHANSSON B; KLEIN G
Journal article: CELLULAR IMMUNOLOGY. 1984;83(1):136-141
EBNA-SPECIFIC LIF PRODUCTION OF HUMAN-LYMPHOCYTE SUBSETS
SZIGETI R; MASUCCI G; EHLINHENRIKSSON B; BENDTZEN K; HENLE G; HENLE W; KLEIN G; KLEIN E
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1983;32(5):609-616
GAMMA-INTERFERON (IFN-GAMMA) PRODUCED DURING EFFECTOR AND TARGET INTERACTIONS RENDERS TARGET-CELLS LESS SUSCEPTIBLE TO NK-CELL-MEDIATED LYSIS
GRONBERG A; KIESSLING R; MASUCCI G; GUEVARA LA; ERIKSSON E; KLEIN G
Journal article: JOURNAL OF IMMUNOLOGICAL METHODS. 1983;63(1):57-67
COMPARISON OF HIGHLY NK ACTIVE HUMAN-LYMPHOCYTE SUBSETS SEPARATED BY VARIOUS PROCEDURES INVOLVING E, EA ROSETTING, DENSITY GRADIENTS AND ADHERENCE TO IMMUNE-COMPLEXES
MASUCCI G; MASUCCI MG; BEJARANO MT; KLEIN E
Journal article: CELLULAR IMMUNOLOGY. 1983;76(2):311-321
LARGE GRANULAR LYMPHOCYTES INHIBIT THE INVITRO GROWTH OF AUTOLOGOUS EPSTEIN-BARR VIRUS-INFECTED B-CELLS
MASUCCI MG; BEJARANO MT; MASUCCI G; KLEIN E
Journal article: MOLECULAR IMMUNOLOGY. 1982;19(10):1323-1329
NATURAL-KILLER ACTIVITY OF HUMAN-BLOOD LYMPHOCYTES
KLEIN E; MASUCCI MG; MASUCCI G; VANKY F
Journal article: ORVOSI HETILAP. 1982;123(20):1217-1221
[Leukocyte migration inhibition elicited by Epstein-Barr virus antigen. Reaction potential in infectious mononucleosis as well as in states of immune deficiency and immunosuppression].
Szigeti R; Klein E; Masucci MG; Ernberg I; Masucci G; Svedmyr E; Klein G
Journal article: CELLULAR IMMUNOLOGY. 1982;69(1):21-33
ACTIVATION OF HUMAN-BLOOD LYMPHOCYTE SUBSETS FOR CYTO-TOXIC POTENTIAL
MASUCCI G; MASUCCI MG; KLEIN E
Journal article: CELLULAR IMMUNOLOGY. 1982;69(1):166-174
HUMAN-BLOOD LYMPHOCYTE SUBSETS SEPARATED ON THE BASIS OF NYLON ADHERENCE, SRBC AND EA ROSETTING - NATURAL CYTO-TOXICITY AND CHARACTERIZATION WITH MONOCLONAL REAGENTS
MASUCCI G; MASUCCI MG; KLEIN E
Journal article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1982;68(2):179-195
Human Lymphoma-Lymphoma Hybrids and Lymphoma-Leukemia Hybrids. I. Isolation, Characterization, Cell Surface Markers, and B-Cell Markers23
Zeuthen J; Klein G; Ber R; Masucci G; Bisballe S; Povey S; Terasaki P; Ralph P
Journal article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1982;68(2):179-195
HUMAN LYMPHOMA-LYMPHOMA HYBRIDS AND LYMPHOMA-LEUKEMIA HYBRIDS .1. ISOLATION, CHARACTERIZATION, CELL-SURFACE MARKERS, AND B-CELL MARKERS .7.
ZEUTHEN J; KLEIN G; BER R; MASUCCI G; BISBALLE S; POVEY S; TERASAKI P; RALPH P
Journal article: CANCER RESEARCH. 1981;41(11):4292-4301
CELL-MEDIATED IMMUNE-REACTIONS IN 3 PATIENTS WITH MALIGNANT LYMPHOPROLIFERATIVE DISEASES IN REMISSION AND ABNORMALLY HIGH EPSTEIN-BARR VIRUS-ANTIBODY TITERS
MASUCCI MG; SZIGETI R; ERNBERG I; BJORKHOLM M; MELLSTEDT H; HENLE G; HENLE W; PEARSON G; MASUCCI G; SVEDMYR E; JOHANSSON B; KLEIN G
Journal article: CANCER RESEARCH. 1981;41(11):4284-4291
CELLULAR IMMUNE DEFECTS TO EPSTEIN-BARR VIRUS-DETERMINED ANTIGENS IN YOUNG MALES
MASUCCI MG; SZIGETI R; ERNBERG I; MASUCCI G; KLEIN G; CHESSELS J; SIEFF C; LIE S; GLOMSTEIN A; BUSINCO L; HENLE W; HENLE G; PEARSON G; SAKAMOTO K; PURTILO DT
Journal article: CANCER RESEARCH. 1981;41(11):4210-4215
T-CELL RESPONSE TO B-CELLS AND EPSTEIN-BARR VIRUS-ANTIGENS IN INFECTIOUS MONONUCLEOSIS
KLEIN E; ERNBERG I; MASUCCI MG; SZIGETI R; WU YT; MASUCCI G; SVEDMYR E
Journal article: NATURE. 1980;288(5791):594-596
INTERFERON SUPPRESSES ANTIGEN-INDUCED AND MITOGEN-INDUCED LEUKOCYTE MIGRATION-INHIBITION
SZIGETI R; MASUCCI MG; MASUCCI G; KLEIN E; KLEIN G
Journal article: CELLULAR IMMUNOLOGY. 1980;52(2):247-254
INVITRO GENERATION OF K562 KILLERS IN HUMAN T-LYMPHOCYTE SUBSETS
MASUCCI G; POROS A; SEELEY JK; KLEIN E
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1980;77(6):3620-3624
TARGET SELECTIVITY OF INTERFERON-INDUCED HUMAN KILLER LYMPHOCYTES RELATED TO THEIR FC-RECEPTOR EXPRESSION
MASUCCI MG; MASUCCI G; KLEIN E; BERTHOLD W
Journal article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1980;64(4):725-738
HYBRIDIZATION OF A MYELOID LEUKEMIA-DERIVED HUMAN CELL-LINE (K562) WITH A HUMAN BURKITT-LYMPHOMA LINE (P3HR-1)
KLEIN G; ZEUTHEN J; ERIKSSON I; TERASAKI P; BERNOCO M; ROSEN A; MASUCCI G; POVEY S; BER R
Journal article: SOMATIC CELL GENETICS. 1980;6(1):89-99
SOMATIC HYBRIDS BETWEEN A HIGH NK-SENSITIVE LYMPHOID (YACIR) AND SEVERAL LOW SENSITIVE SARCOMA OR L-CELL-DERIVED MOUSE LINES EXHIBIT LOW SENSITIVITY
AHRLUND-RICHTER L; KLEIN E; MASUCCI G
Journal article: JOURNAL OF IMMUNOLOGY. 1979;123(3):1303-1311
STUDIES ON CYTOTOXICITY GENERATED IN HUMAN MIXED LYMPHOCYTE-CULTURES .2. ANTI-K562 EFFECTORS ARE DISTINCT FROM ALLOSPECIFIC CTL AND CAN BE GENERATED FROM NK-DEPLETED T-CELLS
SEELEY JK; MASUCCI G; POROS A; KLEIN E; GOLUB SH
Journal article: TUMORI. 1977;63(4):381-386
ITALIAN CASE OF NASOPHARYNGEAL CARCINOMA CORRELATED WITH EPSTEIN-BARR VIRUS SPECIFIC ANTIGENS
SCOLOZZI R; MASUCCI G; CASSAI E; PANSINI R
Journal article: INTERNATIONAL JOURNAL OF CANCER. 1976;17(2):197-203
PERSISTENCE OF EPSTEIN-BARR VIRAL NUCLEAR ANTIGEN (EBNA) IN CELLS ENTERING EB VIRAL CYCLE
ERNBERG I; MASUCCI G; KLEIN G
Show more

All other publications

Letter: ACTA ONCOLOGICA. 2022;61(7):869-873
Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial
Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersall P; Edback U; Wickstrom S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzen B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Review: LAKARTIDNINGEN. 2021;118:21114
[Overview of immune-related side effects from immune checkpoint inhibitors. Part 2: Endocrine, rheumatologic and skin toxicity].
Helgadottir H; Falkenius J; Eriksson H; Girnita A; Sahlberg L; Bensing S; Chatzidionysiou K; Masucci G; Ullenhag G
Preprint: BIORXIV. 2021
SRF-CLICAL: an approach for patient risk stratification using random forest models
Simao FA; Hieta R; Pulman JA; Madonna G; Ascierto PA; Lewensohn R; Masucci GV
Corrigendum: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(6):1407
Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting (vol 35, pg 105, 2021)
Krakowski I; Bottai M; Habel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Editorial comment: ACTA DERMATO-VENEREOLOGICA. 2020;100(18):adv00334-0
Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma
Eriksson H; Hansson J; Krynitz B; Masucci G; Girnita A; Lapins J; Huen AO; Tawbi HA; Davies MA; Tetzlaff MT; Curry JL
Conference publication: JOURNAL OF TRANSLATIONAL MEDICINE. 2020;18
Toward transcriptomics-based prediction of response to Immune Checkpoint Inhibitor in patients with malignant melanoma
Mallardo D; Alexeyenko A; Capone M; Madonna G; Ong S; Warren S; Viktorsson K; Franzen B; Tuffanelli M; Curvietto M; Vanella V; Festino L; Vitale M; Scognamiglio G; Beechem J; Botti G; Cesano A; Lewensohn R; Masucci GV; Ascierto PA
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15)
Effectiveness of PD1-inhibitors in advanced Merkel cell carcinoma: Real life data in a Swedish cohort.
Bjorn-Andtback H; Masucci GV; Villabona LEE
Conference publication: JOURNAL OF TRANSLATIONAL MEDICINE. 2019;18:3603
Gender differences in prognostic value of immune-related biomarkers in colon cancer patients randomized to surgery or surgery and adjuvant chemotherapy treatment
Villabona L; Karlsson J; Masucci G; Ragnhammar P
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):e21047
Prognostic differences and the effect of radiotherapy on survival in Merkel cell carcinoma: A retrospective analysis of a Swedish cohort.
Bjorn-Andtback H; Masucci GV; Bjornhagen-Safwenberg V; Lui W-O; Villabona LEE
Book chapter: HANDBOOK OF BIOMARKERS AND PRECISION MEDICINE. 2019;p. 8-18
In Search of Predictive Biomarkers in Cancer Immunotherapy
Masucci G; Ascierto PA; Villabona L
Conference publication: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2019;7
Real World data analysis related to metastatic melanoma patients treated with immunotherapy from 2012 to 2018 at Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" of Napoli, Italy
Madonna G; Capone M; Tuffanelli M; Curvietto M; Paone M; Esposito A; Sorrentino A; Palla M; Scarpato L; Mallardo D; Simeone E; Grimaldi A; Viktorsson K; Villabona L; Lewensohn R; Masucci G; Ascierto PA
Conference publication: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2019;7
PD-1 checkpoint blockade in advanced melanoma patients: Neutrophils, NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
de Coana YP; Wolodarski M; Avila IVDH; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15)
Gender differences in prognostic value of immune-related biomarkers in colon cancer patients randomized to surgery or surgery and adjuvant chemotherapy treatment.
Villabona L; Masucci GV; Ragnhammar P
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2018;6(9):a14
Surgical removal of metastatic lesions increases T-cell reactivity to tumor-associated antigens in stage III melanoma patients
de Coana YP; Gunnarsdottir FB; Wolodarski M; Brage SE; Masucci G; Hansson J; Kiessling R
Conference publication: CANCER RESEARCH. 2018;78(13):lb-116-lb-116
Myeloid derived suppressor cells and NK cells are correlated with clinical benefit and survival in advanced melanoma patients treated with PD-1 blocking antibodies nivolumab and pembrolizumab
De Coana YP; Wolodarski M; Avila IVDH; Masucci GV; Hansson J; Kiessling R
Conference publication: CANCER RESEARCH. 2018;78(13):ct032
Adoptive T cell transfer combined with DC vaccination in patients with metastatic melanoma
Wickstrom SL; Lovgren T; Wolodarski M; Edback U; Martell E; Markland K; Nystrom M; Lundqvist A; Jacobsson H; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Conference publication: JOURNAL OF TRANSLATIONAL MEDICINE. 2018;17:e21601
Prognostic differences between male and female patients in virus-negative Merkel cell carcinoma
Bjorn-Andtback H; Bjornhagen-Safwenberg V; Lui W-O; Masucci GV; Villabona L
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15)
Prognostic differences between male and female patients in virus-negative Merkel cell carcinoma.
Villabona L; Bjorn-Andtback H; Bjornhagen-Safwenberg V; Lui W-O; Masucci GV
Editorial comment: JOURNAL OF TRANSLATIONAL MEDICINE. 2017;15(1):223
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
Masucci GV; Cesano A; Eggermont A; Fox BA; Wang E; Marincola FM; Ciliberto G; Dobbin K; Puzanov I; Taube J; Wargo J; Butterfield LH; Villabona L; Thurin M; Postow MA; Sondel PM; Demaria S; Agarwala S; Ascierto PA
Letter: ANNALS OF ONCOLOGY. 2017;28(7):1672-1673
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma
Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
Conference publication: EUROPEAN JOURNAL OF CANCER. 2017;72:S122-S123
Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006
Long GV; Blank C; Ribas A; Mortier L; Carlino MS; Lotem M; Lorigan P; Neyns B; Petrella TM; Puzanov I; Richtig E; O'Day SJ; Masucci G; Lebbe C; Steven N; Lutzky J; Hille D; Ebbinghaus S; Ibrahim N; McNeil C
Conference publication: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2016;4(Suppl 1):82
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
Lundqvist A; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Sanz LM; Liang S; Murray S; Larsson O; Kiessling R; Mao Y; Sidhom J-W; Bessell CA; Havel J; Schneck J; Chan TA; Sachsenmeier E; Woods D; Berglund A; Ramakrishnan R; Sodre A; Weber J; Zappasodi R; Li Y; Qi J; Wong P; Sirard C; Postow M; Newman W; Koon H; Velcheti V; Callahan MK; Wolchok JD; Merghoub T; Lum LG; Choi M; Thakur A; Deol A; Dyson G; Shields A; Haymaker C; Uemura M; Murthy R; James M; Wang D; Brevard J; Monaghan C; Swann S; Geib J; Cornfeld M; Chunduru S; Agrawal S; Yee C; Wargo J; Patel SP; Amaria R; Tawbi H; Glitza I; Woodman S; Hwu W-J; Davies MA; Hwu P; Overwijk WW; Bernatchez C; Diab A; Massarelli E; Segal NH; Ribrag V; Melero I; Gangadhar TC; Urba W; Schadendorf D; Ferris RL; Houot R; Morschhauser F; Logan T; Luke JJ; Sharfman W; Barlesi F; Ott PA; Mansi L; Kummar S; Salles G; Carpio C; Meier R; Krishnan S; McDonald D; Maurer M; Gu X; Neely J; Suryawanshi S; Levy R; Khushalani N; Wu J; Zhang J; Basher F; Rubinstein M; Bucsek M; Qiao G; MacDonald C; Hylander B; Repasky E; Chatterjee S; Daenthanasanmak A; Chakraborty P; Toth K; Meek M; Garrett-Mayer E; Nishimura M; Paulos C; Beeson C; Yu X; Mehrotra S; Zhao F; Evans K; Xiao C; Holtzhausen A; Hanks BA; Scharping N; Menk AV; Moreci R; Whetstone R; Dadey R; Watkins S; Ferris R; Delgoffe GM; Peled J; Devlin S; Staffas A; Lumish M; Rodriguez KP; Ahr K; Perales M; Giralt S; Taur Y; Pamer E; van den Brink MRM; Jenq R; Annels N; Pandha H; Simpson G; Mostafid H; Harrington K; Melcher A; Grose M; Davies B; Au G; Karpathy R; Shafren D; Ricca J; Merghoub T; Wolchok JD; Zamarin D; Batista L; Marliot F; Vasaturo A; Carpentier S; Poggionovo C; Frayssinet V; Fieschi J; Van den Eynde M; Pagès F; Galon J; Hermitte F; Smith SG; Nguyen K; Ravindranathan S; Koppolu B; Zaharoff D; Schvartsman G; Bassett R; McQuade JL; Haydu LE; Davies MA; Tawbi H; Glitza I; Kline D; Chen X; Fosco D; Kline J; Overacre A; Chikina M; Brunazzi E; Shayan G; Horne W; Kolls J; Ferris RL; Delgoffe GM; Bruno TC; Workman C; Vignali D; Adusumilli PS; Ansa-Addo EA; Li Z; Gerry A; Sanderson JP; Howe K; Docta R; Gao Q; Bagg EAL; Tribble N; Maroto M; Betts G; Bath N; Melchiori L; Lowther DE; Ramachandran I; Kari G; Basu S; Binder-Scholl G; Chagin K; Pandite L; Holdich T; Amado R; Zhang H; Glod J; Bernstein D; Jakobsen B; Mackall C; Wong R; Silk JD; Adams K; Hamilton G; Bennett AD; Brett S; Jing J; Quattrini A; Saini M; Wiedermann G; Gerry A; Jakobsen B; Binder-Scholl G; Brewer J; Duong M; Lu A; Chang P; Mahendravada A; Shinners N; Slawin K; Spencer DM; Foster AE; Bayle JH; Bergamaschi C; Ng SSM; Nagy B; Jensen S; Hu X; Alicea C; Fox B; Felber B; Pavlakis G; Chacon J; Yamamoto T; Garrabrant T; Cortina L; Powell DJ; Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Dolton G; Szomolay B; Ott S; Lyngaa R; Hadrup SR; Sewell AK; Svane IM; Fan A; Kumai T; Celis E; Frank I; Stramer A; Blaskovich MA; Wardell S; Fardis M; Bender J; Lotze MT; Goff SL; Zacharakis N; Assadipour Y; Prickett TD; Gartner JJ; Somerville R; Black M; Xu H; Chinnasamy H; Kriley I; Lu L; Wunderlich J; Robbins PF; Rosenberg S; Feldman SA; Trebska-McGowan K; Kriley I; Malekzadeh P; Payabyab E; Sherry R; Rosenberg S; Goff SL; Gokuldass A; Blaskovich MA; Kopits C; Rabinovich B; Lotze MT; Green DS; Kamenyeva O; Zoon KC; Annunziata CM; Hammill J; Helsen C; Aarts C; Bramson J; Harada Y; Yonemitsu Y; Helsen C; Hammill J; Mwawasi K; Denisova G; Bramson J; Giri R; Jin B; Campbell T; Draper LM; Stevanovic S; Yu Z; Weissbrich B; Restifo NP; Trimble CL; Rosenberg S; Hinrichs CS; Tsang K; Fantini M; Hodge JW; Fujii R; Fernando I; Jochems C; Heery C; Gulley J; Soon-Shiong P; Schlom J; Jing W; Gershan J; Blitzer G; Weber J; McOlash L; Johnson BD; Kiany S; Gangxiong H; Kleinerman ES; Klichinsky M; Ruella M; Shestova O; Kenderian S; Kim M; Scholler J; June CH; Gill S; Moogk D; Zhong S; Yu Z; Liadi I; Rittase W; Fang V; Dougherty J; Perez-Garcia A; Osman I; Zhu C; Varadarajan N; Restifo NP; Frey A; Krogsgaard M; Landi D; Fousek K; Mukherjee M; Shree A; Joseph S; Bielamowicz K; Byrd T; Ahmed N; Hegde M; Lee S; Byrd D; Thompson J; Bhatia S; Tykodi S; Delismon J; Chu L; Abdul-Alim S; Ohanian A; DeVito AM; Riddell S; Margolin K; Magalhaes I; Mattsson J; Uhlin M; Nemoto S; Villarroel PP; Nakagawa R; Mule JJ; Mailloux AW; Mata M; Nguyen P; Gerken C; DeRenzo C; Spencer DM; Gottschalk S; Mathieu M; Pelletier S; Stagg J; Turcotte S; Minutolo N; Sharma P; Tsourkas A; Powell DJ; Mockel-Tenbrinck N; Mauer D; Drechsel K; Barth C; Freese K; Kolrep U; Schult S; Assenmacher M; Kaiser A; Mullinax J; Hall M; Le J; Kodumudi K; Royster E; Richards A; Gonzalez R; Sarnaik A; Pilon-Thomas S; Nielsen M; Krarup-Hansen A; Hovgaard D; Petersen MM; Loya AC; Junker N; Svane IM; Rivas C; Parihar R; Gottschalk S; Rooney CM; Qin H; Nguyen S; Su P; Burk C; Duncan B; Kim B-H; Kohler ME; Fry T; Rao AA; Teyssier N; Pfeil J; Sgourakis N; Salama S; Haussler D; Richman SA; Nunez-Cruz S; Gershenson Z; Mourelatos Z; Barrett D; Grupp S; Milone M; Rodriguez-Garcia A; Robinson MK; Adams GP; Powell DJ; Santos J; Havunen R; Siurala M; Cervera-Carrascón V; Parviainen S; Antilla M; Hemminki A; Sethuraman J; Santiago L; Chen JQ; Dai Z; Wardell S; Bender J; Lotze MT; Sha H; Su S; Ding N; Liu B; Stevanovic S; Pasetto A; Helman SR; Gartner JJ; Prickett TD; Robbins PF; Rosenberg SA; Hinrichs CS; Bhatia S; Burgess M; Zhang H; Lee T; Klingemann H; Soon-Shiong P; Nghiem P; Kirkwood JM; Rossi JM; Sherman M; Xue A; Shen Y-W; Navale L; Rosenberg SA; Kochenderfer JN; Bot A; Veerapathran A; Gokuldass A; Stramer A; Sethuraman J; Blaskovich MA; Wiener D; Frank I; Santiago L; Rabinovich B; Fardis M; Bender J; Lotze MT; Waller EK; Li J-M; Petersen C; Blazar BR; Li J; Giver CR; Wang Z; Grossenbacher SK; Sturgill I; Canter RJ; Murphy WJ; Zhang C; Burger MC; Jennewein L; Waldmann A; Mittelbronn M; Tonn T; Steinbach JP; Wels WS; Williams JB; Zha Y; Gajewski TF; Williams LC; Krenciute G; Kalra M; Louis C; Gottschalk S; Xin G; Schauder D; Jiang A; Joshi N; Cui W; Zeng X; Menk AV; Scharping N; Delgoffe GM; Zhao Z; Hamieh M; Eyquem J; Gunset G; Bander N; Sadelain M; Askmyr D; Abolhalaj M; Lundberg K; Greiff L; Lindstedt M; Angell HK; Kim K-M; Kim S-T; Kim S; Sharpe AD; Ogden J; Davenport A; Hodgson DR; Barrett C; Lee J; Kilgour E; Hanson J; Caspell R; Karulin A; Lehmann P; Ansari T; Schiller A; Sundararaman S; Lehmann P; Hanson J; Roen D; Karulin A; Lehmann P; Ayers M; Levitan D; Arreaza G; Liu F; Mogg R; Bang Y-J; O’Neil B; Cristescu R; Friedlander P; Wassman K; Kyi C; Oh W; Bhardwaj N; Bornschlegl S; Gustafson MP; Gastineau DA; Parney IF; Dietz AB; Carvajal-Hausdorf D; Mani N; Velcheti V; Schalper K; Rimm D; Chang S; Levy R; Kurland J; Krishnan S; Ahlers CM; Jure-Kunkel M; Cohen L; Maecker H; Kohrt H; Chen S; Crabill G; Pritchard T; McMiller T; Pardoll D; Pan F; Topalian S; Danaher P; Warren S; Dennis L; White AM; D’Amico L; Geller M; Disis ML; Beechem J; Odunsi K; Fling S; Derakhshandeh R; Webb TJ; Dubois S; Conlon K; Bryant B; Hsu J; Beltran N; Müller J; Waldmann T; Duhen R; Duhen T; Thompson L; Montler R; Weinberg A; Kates M; Early B; Yusko E; Schreiber TH; Bivalacqua TJ; Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng J; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert T; Ribas A; McClanahan TK; Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Nebozhyn M; Lunceford J; Joe A; Cheng J; Plimack E; Ott PA; McClanahan TK; Loboda A; Kaufman DR; Forrest-Hay A; Guyre CA; Narumiya K; Delcommenne M; Hirsch HA; Deshpande A; Reeves J; Shu J; Zi T; Michaelson J; Law D; Trehu E; Sathyanaryanan S; Hodkinson BP; Hutnick NA; Schaffer ME; Gormley M; Hulett T; Jensen S; Ballesteros-Merino C; Dubay C; Afentoulis M; Reddy A; David L; Fox B; Jayant K; Agrawal S; Agrawal R; Jeyakumar G; Kim S; Kim H; Silski C; Suisham S; Heath E; Vaishampayan U; Vandeven N; Viller NN; O’Connor A; Chen H; Bossen B; Sievers E; Uger R; Nghiem P; Johnson L; Kao H-F; Hsiao C-F; Lai S-C; Wang C-W; Ko J-Y; Lou P-J; Lee T-J; Liu T-W; Hong R-L; Kearney SJ; Black JC; Landis BJ; Koegler S; Hirsch B; Gianani R; Kim J; He M-X; Zhang B; Su N; Luo Y; Ma X-J; Park E; Kim DW; Copploa D; Kothari N; doo Chang Y; Kim R; Kim N; Lye M; Wan E; Kim N; Lye M; Wan E; Kim N; Lye M; Wan E; Knaus HA; Berglund S; Hackl H; Karp JE; Gojo I; Luznik L; Hong HS; Koch SD; Scheel B; Gnad-Vogt U; Kallen K-J; Wiegand V; Backert L; Kohlbacher O; Hoerr I; Fotin-Mleczek M; Billingsley JM; Koguchi Y; Conrad V; Miller W; Gonzalez I; Poplonski T; Meeuwsen T; Howells-Ferreira A; Rattray R; Campbell M; Bifulco C; Dubay C; Bahjat K; Curti B; Urba W; Vetsika E-K; Kallergi G; Aggouraki D; Lyristi Z; Katsarlinos P; Koinis F; Georgoulias V; Kotsakis A; Martin NT; Aeffner F; Kearney SJ; Black JC; Cerkovnik L; Pratte L; Kim R; Hirsch B; Krueger J; Gianani R; Martínez-Usatorre A; Jandus C; Donda A; Carretero-Iglesia L; Speiser DE; Zehn D; Rufer N; Romero P; Panda A; Mehnert J; Hirshfield KM; Riedlinger G; Damare S; Saunders T; Sokol L; Stein M; Poplin E; Rodriguez-Rodriguez L; Silk A; Chan N; Frankel M; Kane M; Malhotra J; Aisner J; Kaufman HL; Ali S; Ross J; White E; Bhanot G; Ganesan S; Monette A; Bergeron D; Amor AB; Meunier L; Caron C; Morou A; Kaufmann D; Liberman M; Jurisica I; Mes-Masson A-M; Hamzaoui K; Lapointe R; Mongan A; Ku Y-C; Tom W; Sun Y; Pankov A; Looney T; Au-Young J; Hyland F; Conroy J; Morrison C; Glenn S; Burgher B; Ji H; Gardner M; Mongan A; Omilian AR; Conroy J; Bshara W; Angela O; Burgher B; Ji H; Glenn S; Morrison C; Mongan A; Obeid JM; Erdag G; Smolkin ME; Deacon DH; Patterson JW; Chen L; Bullock TN; Slingluff CL; Obeid JM; Erdag G; Deacon DH; Slingluff CL; Bullock TN; Loffredo JT; Vuyyuru R; Beyer S; Spires VM; Fox M; Ehrmann JM; Taylor KA; Korman AJ; Graziano RF; Page D; Sanchez K; Ballesteros-Merino C; Martel M; Bifulco C; Urba W; Fox B; Patel SP; De Macedo MP; Qin Y; Reuben A; Spencer C; Guindani M; Bassett R; Wargo J; Racolta A; Kelly B; Jones T; Polaske N; Theiss N; Robida M; Meridew J; Habensus I; Zhang L; Pestic-Dragovich L; Tang L; Sullivan RJ; Logan T; Khushalani N; Margolin K; Koon H; Olencki T; Hutson T; Curti B; Roder J; Blackmon S; Roder H; Stewart J; Amin A; Ernstoff MS; Clark JI; Atkins MB; Kaufman HL; Sosman J; Weber J; McDermott DF; Weber J; Kluger H; Halaban R; Snzol M; Roder H; Roder J; Asmellash S; Steingrimsson A; Blackmon S; Sullivan RJ; Wang C; Roman K; Clement A; Downing S; Hoyt C; Harder N; Schmidt G; Schoenmeyer R; Brieu N; Yigitsoy M; Madonna G; Botti G; Grimaldi A; Ascierto PA; Huss R; Athelogou M; Hessel H; Harder N; Buchner A; Schmidt G; Stief C; Huss R; Binnig G; Kirchner T; Sellappan S; Thyparambil S; Schwartz S; Cecchi F; Nguyen A; Vaske C; Hembrough T; Spacek J; Vocka M; Zavadova E; Skalova H; Dundr P; Petruzelka L; Francis N; Tilman RT; Hartmann A; Netikova I; Ballesteros-Merino C; Stump J; Tufman A; Berger F; Neuberger M; Hatz R; Lindner M; Sanborn RE; Handy J; Fox B; Bifulco C; Huber RM; Winter H; Reu S; Sun C; Xiao W; Tian Z; Arora K; Desai N; Kulkarni A; Rajurkar M; Rivera M; Deshpande V; Ting D; Tsai K; Nosrati A; Goldinger S; Hamid O; Algazi A; Tumeh P; Hwang J; Liu J; Chen L; Dummer R; Rosenblum M; Daud A; Tsao T-S; Ashworth-Sharpe J; Johnson D; Bhaumik S; Bieniarz C; Couto J; Farrell M; Ghaffari M; Habensus I; Hubbard A; Jones T; Kelly B; Kosmeder J; Lee C; Marner E; Meridew J; Polaske N; Racolta A; Uribe D; Zhang H; Zhang J; Zhang W; Zhu Y; Morrison L; Pestic-Dragovich L; Tang L; Tsujikawa T; Borkar RN; Azimi V; Kumar S; Thibault G; Mori M; El Rassi E; Clayburgh DR; Kulesz-Martin MF; Flint PW; Coussens LM; Villabona L; Masucci GV; Geiss G; Birditt B; Mei Q; Huang A; White AM; Eagan MA; Ignacio E; Elliott N; Dunaway D; Dennis L; Warren S; Beechem J; Dunaway D; Jung J; Merritt C; Sprague I; Webster P; Liang Y; Warren S; Beechem J; Wenthe J; Enblad G; Karlsson H; Essand M; Savoldo B; Dotti G; Höglund M; Brenner MK; Hagberg H; Loskog A; Bernett MJ; Moore GL; Hedvat M; Bonzon C; Chu S; Rashid R; Avery KN; Muchhal U; Desjarlais J; Hedvat M; Bernett MJ; Moore GL; Bonzon C; Rashid R; Chu S; Avery KN; Muchhal U; Desjarlais J; Kraman M; Kmiecik K; Allen N; Faroudi M; Zimarino C; Wydro M; Doody J; Srinivasa SP; Govindappa N; Reddy P; Dubey A; Periyasamy S; Adekandi M; Dey C; Joy M; van Loo PF; Veninga H; Shamsili S; Throsby M; Dolstra H; Bakker L; Alva A; Gschwendt J; Loriot Y; Bellmunt J; Feng D; Poehlein C; Powles T; Antonarakis ES; Drake CG; Wu H; Poehlein C; De Bono J; Bannerji R; Byrd J; Gregory G; Opat S; Shortt J; Yee AJ; Raje N; Thompson S; Balakumaran A; Kumar S; Rini BI; Choueiri TK; Mariani M; Albiges L; Haanen JB; Atkins MB; Larkin J; Schmidinger M; Magazzù D; di Pietro A; Motzer RJ; Borch TH; Andersen R; Kongsted P; Pedersen M; Nielsen M; Met Ö; Donia M; Svane IM; Boudadi K; Wang H; Vasselli J; Baughman JE; Wigginton J; Abdallah R; Ross A; Drake CG; Antonarakis ES; Canter RJ; Park J; Wang Z; Grossenbacher S; Luna JI; Withers S; Culp W; Chen M; Monjazeb A; Kent MS; Murphy WJ; Chandran S; Somerville R; Wunderlich J; Danforth D; Yang J; Sherry R; Klebanoff C; Goff S; Paria B; Sabesan A; Srivastava A; Rosenberg SA; Kammula U; Curti B; Richards J; Faries M; Andtbacka RHI; Grose M; Shafren D; Diaz LA; Le DT; Yoshino T; André T; Bendell J; Koshiji M; Zhang Y; Kang SP; Lam B; Jäger D; Bauer TM; Wang JS; Lee JK; Manji GA; Kudchadkar R; Kauh JS; Tang S; Laing N; Falchook G; Garon EB; Halmos B; Rina H; Leighl N; Lee SS; Walsh W; Dragnev K; Piperdi B; Rodriguez LP-A; Shinwari N; Wei Z; Gustafson MP; Maas ML; Deeds M; Armstrong A; Bornschlegl S; Peterson T; Steinmetz S; Gastineau DA; Parney IF; Dietz AB; Herzog T; Backes FJ; Copeland L; Del Pilar Estevez Diz M; Hare TW; Huh W; Kim B-G; Moore KM; Oaknin A; Small W; Tewari KS; Monk BJ; Kamat AM; Bellmunt J; Choueiri TK; Nam K; De Santis M; Dreicer R; Hahn NM; Perini R; Siefker-Radtke A; Sonpavde G; de Wit R; Witjes JA; Keefe S; Bajorin D; Kline J; Armand P; Kuruvilla J; Moskowitz C; Hamadani M; Ribrag V; Zinzani PL; Chlosta S; Thompson S; Balakumaran A; Bartlett N; Kyi C; Sabado R; Saenger Y; William L; Donovan MJ; Sacris E; Mandeli J; Salazar AM; Friedlander P; Bhardwaj N; Powderly J; Brody J; Nemunaitis J; Emens L; Luke JJ; Patnaik A; McCaffery I; Miller R; Laport G; Coveler AL; Smith DC; Grilley-Olson JE; Gajewski TF; Goel S; Gardai SJ; Law C-L; Means G; Manley T; Curti B; Marrone KA; Rosner G; Anagnostou V; Riemer J; Wakefield J; Zanhow C; Baylin S; Gitlitz B; Brahmer J; McDermott DF; Signoretti S; Li W; Schloss C; Michot J-M; Armand P; Ding W; Ribrag V; Christian B; Balakumaran A; Marinello P; Chlosta S; Zhang Y; Shipp M; Zinzani PL; Najjar YG; Lin; Butterfield LH; Tarhini AA; Davar D; Zarour H; Rush E; Sander C; Kirkwood JM; Fu S; Bauer T; Molineaux C; Bennett MK; Orford KW; Papadopoulos KP; Padda SK; Shah SA; Colevas AD; Narayanan S; Fisher GA; Supan D; Wakelee HA; Aoki R; Pegram MD; Villalobos VM; Liu J; Takimoto CH; Chao M; Volkmer J-P; Majeti R; Weissman IL; Sikic BI; Page D; Yu W; Conlin A; Ruzich J; Lewis S; Acheson A; Kemmer K; Perlewitz K; Moxon NM; Mellinger S; Bifulco C; Martel M; Koguchi Y; Fox B; Urba W; McArthur H; Pedersen M; Westergaard MCW; Borch TH; Nielsen M; Kongsted P; Juhler-Nøttrup T; Donia M; Svane IM; Desai J; Markman B; Sandhu S; Gan H; Friedlander ML; Tran B; Meniawy T; Lundy J; Colyer D; Ameratunga M; Norris C; Yang J; Li K; Wang L; Luo L; Qin Z; Mu S; Tan X; Song J; Millward M; Katz MHG; Bauer TW; Varadhachary GR; Acquavella N; Merchant N; Petroni G; Slingluff CL; Rahma OE; Rini BI; Powles T; Chen M; Song Y; Puhlmann M; Atkins MB; Sathyanaryanan S; Hirsch HA; Shu J; Deshpande A; Khattri A; Reeves J; Zi T; Brisson R; Harvey C; Michaelson J; Law D; Seiwert T; Shah J; Mateos MV; Matsumoto M; Blacklock H; Rocafiguera AO; Goldschmidt H; Iida S; Yehuda DB; Ocio E; Rodríguez-Otero P; Jagannath S; Lonial S; Kher U; Marinello P; San-Miguel J; Shah J; Lonial S; de Oliveira MR; Yimer H; Mateos MV; Rifkin R; Schjesvold F; Ocio E; Rodríguez-Otero P; San-Miguel J; Ghori R; Marinello P; Jagannath S; Spreafico A; Lee V; Ngan RKC; To KF; Ahn MJ; Ng QS; Hong R-L; Lin J-C; Swaby RF; Gause C; Saraf S; Chan ATC; Lam E; Tannir NM; Meric-Bernstam F; Vaishampayan U; Orford KW; Molineaux C; Gross M; MacKinnon A; Whiting S; Voss M; Yu EY; Wu H; Schloss C; Albertini MR; Ranheim EA; Hank JA; Zuleger C; McFarland T; Collins J; Clements E; Weber S; Weigel T; Neuman H; Hartig G; Mahvi D; Henry M; Gan J; Yang R; Carmichael L; Kim K; Gillies SD; Sondel PM; Subbiah V; Murthy R; Noffsinger L; Hendricks K; Bosch M; Lee JM; Lee M-H; Garon EB; Goldman JW; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin YQ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp K; Wallace WD; Zeng G; Elashoff DA; Sharma S; Dubinett SM; Bhardwaj N; Friedlander P; Pavlick AC; Ernstoff MS; Gastman B; Hanks B; Albertini MR; Luke JJ; Keler T; Davis T; Vitale LA; Sharon E; Danaher P; Morishima C; Cheever M; Fling S; Heery CR; Kim JW; Lamping E; Marte J; McMahon S; Cordes L; Fakhrejahani F; Madan R; Tsang K; Jochems C; Salazar R; Zhang M; Helwig C; Schlom J; Gulley JL; Li R; Amrhein J; Cohen Z; Champagne M; Kamat A; Aznar MA; Labiano S; Diaz-Lagares A; Esteller M; Sandoval J; Melero I; Barbee SD; Bellovin DI; Timmer JC; Wondyfraw N; Johnson S; Park J; Chen A; Mkrtichyan M; Razai AS; Jones KS; Hata CY; Gonzalez D; Deveraux Q; Eckelman BP; Borges L; Bhardwaj R; Puri RK; Suzuki A; Leland P; Joshi BH; Bartkowiak T; Jaiswal A; Ager C; Ai M; Budhani P; Chin R; Hong D; Curran M; Hastings WD; Pinzon-Ortiz M; Murakami M; Dobson JR; Quinn D; Wagner JP; Rong X; Shaw P; Dammassa E; Guan W; Dranoff G; Cao A; Fulton RB; Leonardo S; Fraser K; Kangas TO; Ottoson N; Bose N; Huhn RD; Graff J; Lowe J; Gorden K; Uhlik M; Vitale LA; O’Neill T; Widger J; Crocker A; He L-Z; Weidlick J; Sundarapandiyan K; Ramakrishna V; Storey J; Thomas LJ; Goldstein J; Marsh HC; Keler T; Grailer J; Gilden J; Stecha P; Garvin D; Hartnett J; Fan F; Cong M; Cheng Z-JJ; Hinner MJ; Aiba R-SB; Schlosser C; Jaquin T; Allersdorfer A; Berger S; Wiedenmann A; Matschiner G; Schüler J; Moebius U; Rothe C; Shane OA; Horton B; Spranger S; Gajewski TF; Moreira D; Adamus T; Zhao X; Swiderski P; Pal S; Kortylewski M; Kosmides A; Necochea K; Schneck J; Mahoney KM; Shukla SA; Patsoukis N; Chaudhri A; Pham H; Hua P; Bu X; Zhu B; Hacohen N; Wu CJ; Fritsch E; Boussiotis VA; Freeman GJ; Moran AE; Polesso F; Lukaesko L; Weinberg A; Rådestad E; Egevad L; Mattsson J; Sundberg B; Henningsohn L; Levitsky V; Uhlin M; Rafelson W; Reagan JL; Fast L; Sasikumar P; Sudarshan N; Ramachandra R; Gowda N; Samiulla D; Chandrasekhar T; Adurthi S; Mani J; Nair R; Dhudashia A; Gowda N; Ramachandra M; Sankin A; Gartrell B; Cumberbatch K; Huang H; Stern J; Schoenberg M; Zang X; Swanson R; Kornacker M; Evans L; Rickel E; Wolfson M; Valsesia-Wittmann S; Shekarian T; Simard F; Nailo R; Dutour A; Jallas A-C; Caux C; Marabelle A
Conference publication: ANNALS OF ONCOLOGY. 2016;27:vi382
Estimating the percentage of patients with advanced melanoma achieving long-term survival with pembrolizumab (Pembro) treatment in KEYNOTE-006
Blank C; Ma J; Grob JJ; Larkin J; Neyns B; McNeil C; Lotem M; Richtig E; Masucci G; Petrella T; Ribas A; Wang J; Ibrahim N; Anderson KM; Arance A
Review: DRUGS. 2016;76(9):925-945
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):e15102
Analysis of immune-related prognostic markers in colon cancer patients randomized to surgery or surgery and adjuvant cytostatic treatment
Villabona L; Masucci GV; Ragnhammar P
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):3500
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.
Galon J; Mlecnik B; Marliot F; Ou F-S; Bifulco CB; Lugli A; Zlobec I; Rau TT; Hartmann A; Masucci GV; Zavadova E; Ohashi P; Roehrl MHA; Kawakami Y; Torigoe T; Ascierto PA; Marincola F; Sargent DJ; Fox BA; Pages F
Conference publication: JOURNAL OF TRANSLATIONAL MEDICINE. 2016;14
Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs
de Coana YP; Wolodarski M; Yoshimoto Y; Gentilcore G; Poschke I; Masucci GV; Hansson J; Kiessling R
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2016;4(1):a071
Immune monitoring of ipilimumab treated patients reveals enhanced CD4+T cell activation correlated with diminished MDSCs
de Coana YP; Wolodarski M; Yoshimoto Y; Gentilcore G; Poschke I; Masucci GV; Hansson J; Kiessling R
Review: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2016;4:76
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
Review: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2016;4:77
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations
Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
Editorial comment: THE LANCET ONCOLOGY. 2015;16(13):1285-1287
PD-L1 expression as a potential predictive biomarker
Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
Book chapter: DEVELOPMENTS IN T CELL BASED CANCER IMMUNOTHERAPIES: CANCER DRUG DISCOVERY AND DEVELOPMENT. 2015;p. 211-229
T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy
Masucci GV; De Petris L; Lundqvist A; Kiessling R; Lewensohn R
Review: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2014;63(9):977-983
Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
de Coana YP; Masucci G; Hansson J; Kiessling R
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):tps3118
A phase I study of adoptive T-cell therapy with or without dendritic cell vaccination in patients with metastatic melanoma.
Tell R; Mattson J; Adamson L; Poschke I; Engstrom M; Lovpren T; Hansson J; Masuccl GV; Lundqvist A; Kiessling R
Review: JOURNAL OF PATHOLOGY. 2014;232(2):199-209
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
Galon J; Mlecnik B; Bindea G; Angell HK; Berger A; Lagorce C; Lugli A; Zlobec I; Hartmann A; Bifulco C; Nagtegaal ID; Palmqvist R; Masucci GV; Botti G; Tatangelo F; Delrio P; Maio M; Laghi L; Grizzi F; Asslaber M; D'Arrigo C; Vidal-Vanaclocha F; Zavadova E; Chouchane L; Ohashi PS; Hafezi-Bakhtiari S; Wouters BG; Roehrl M; Nguyen L; Kawakami Y; Hazama S; Okuno K; Ogino S; Gibbs P; Waring P; Sato N; Torigoe T; Itoh K; Patel PS; Shukla SN; Wang Y; Kopetz S; Sinicrope FA; Scripcariu V; Ascierto PA; Marincola FM; Fox BA; Pages F
Corrigendum: CANCER IMMUNOLOGY RESEARCH. 2013;1(6):438
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid Derived Suppressor Cells as well as Their Arginase1 Production (vol 1, pg 158, 2013)
de Coana YP; Poschke I; Gentilcore G; Mao Y; Nystrom M; Hansson J; Masucci GV; Kiessling R
Review: JOURNAL OF TRANSLATIONAL MEDICINE. 2013;11:247
HLA-dependent tumour development: a role for tumour associate macrophages?
Marchesi M; Andersson E; Villabona L; Seliger B; Lundqvist A; Kiessling R; Masucci GV
Conference publication: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2013;87(2):S273-S274
Local Control, Patterns of Failure, and Vertebral Compression Fracture After Spine Stereotactic Radiation Therapy for Metastatic Renal Cell Cancer
Thibault I; Al-Omair A; Masucci G; Masson-Cote L; Lochray F; Bjarnason G; Yee A; Korol R; Cheng L; Sahgal A
Review: JOURNAL OF TRANSLATIONAL MEDICINE. 2012;10:205
Cancer classification using the Immunoscore: a worldwide task force
Galon J; Pages F; Marincola FM; Angell HK; Thurin M; Lugli A; Zlobec I; Berger A; Bifulco C; Botti G; Tatangelo F; Britten CM; Kreiter S; Chouchane L; Delrio P; Arndt H; Asslaber M; Maio M; Masucci GV; Mihm M; Vidal-Vanaclocha F; Allison JP; Gnjatic S; Hakansson L; Huber C; Singh-Jasuja H; Ottensmeier C; Zwierzina H; Laghi L; Grizzi F; Ohashi PS; Shaw PA; Clarke BA; Wouters BG; Kawakami Y; Hazama S; Okuno K; Wang E; O'Donnell-Tormey J; Lagorce C; Pawelec G; Nishimura MI; Hawkins R; Lapointe R; Lundqvist A; Khleif SN; Ogino S; Gibbs P; Waring P; Sato N; Torigoe T; Itoh K; Patel PS; Shukla SN; Palmqvist R; Nagtegaal ID; Wang Y; D'Arrigo C; Kopetz S; Sinicrope FA; Trinchieri G; Gajewski TF; Ascierto PA; Fox BA
Editorial comment: JOURNAL OF TRANSLATIONAL MEDICINE. 2012;10:104
Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours
Masucci GV; Wersall P; Kiessling R; Lundqvist A; Lewensohn R
Conference publication: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2011;81(2):S294
Local Control With Stereotactic Body Radiation Therapy (SBRT) For Spinal Metastasis: Is It Dose Or Biology That Matters?
Masucci G; Masson-Cote L; Letourneau D; Atenafu EG; Massicotte E; Lewis S; Rampersaud R; Laperriere N; Fehlings M; Sahgal A
Conference publication: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2011;81(2):S37
Adult Craniopharyngioma Tumors: Long-term Outcomes in Patients Treated with Radiation Therapy
Masson-Cote L; Masucci G; Atenafu EG; Millar B; Menard C; Payne D; Laperriere NJ; Sahgal A
Conference publication: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2009;75(3):S344
Comparison between High and Low Source Activity for Permanent Seed Prostate Brachytherapy with Radioactive I¹²⁵
Masucci G; Donath D; Tetreault-Laflamme A; Hervieux Y; Larouche R; Bahary J; Taussky D
Review: JOURNAL OF TRANSLATIONAL MEDICINE. 2009;7:45
Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology
Tahara H; Sato M; Thurin M; Wang E; Butterfield LH; Disis ML; Fox BA; Lee PP; Khleif SN; Wigginton JM; Ambs S; Akutsu Y; Chaussabel D; Doki Y; Eremin O; Fridman WH; Hirohashi Y; Imai K; Jacobson J; Jinushi M; Kanamoto A; Kashani-Sabet M; Kato K; Kawakami Y; Kirkwood JM; Kleen TO; Lehmann PV; Liotta L; Lotze MT; Maio M; Malyguine A; Masucci G; Matsubara H; Mayrand-Chung S; Nakamura K; Nishikawa H; Palucka AK; Petricoin EF; Pos Z; Ribas A; Rivoltini L; Sato N; Shiku H; Slingluff CL; Streicher H; Stroncek DF; Takeuchi H; Toyota M; Wada H; Wu X; Wulfkuhle J; Yaguchi T; Zeskind B; Zhao Y; Zocca M-B; Marincola FM
Editorial comment: JOURNAL OF TRANSLATIONAL MEDICINE. 2008;6:81
A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
Butterfield LH; Disis ML; Fox BA; Lee PP; Khleif SN; Thurin M; Trinchieri G; Wang E; Wigginton J; Chaussabel D; Coukos G; Dhodapkar M; Hakansson L; Janetzki S; Kleen TO; Kirkwood JM; Maccalli C; Maecker H; Maio M; Malyguine A; Masucci G; Palucka AK; Potter DM; Ribas A; Rivoltini L; Schendel D; Seliger B; Selvan S; Slingluff CLJ; Stroncek DF; Streicher H; Wu X; Zeskind B; Zhao Y; Zocca M-B; Zwierzina H; Marincola FM
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(15):9050
Ancestral HLA haplotypes 62.1 and 8.1 as negative prognostic factors in patients with metastatic malignant melanoma
Helgadottir H; Andersson E; Hansson J; Kiessling R; Masucci GV
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(15):16544
Survival rates in HLA-A2 positive patients, with stage III-IV serous adenocarcinomas of the ovary, correlates with increased expression of COX-2 and iNOS, loss of MHC Class I and II and defects of the antigen processing mechanisms at the tumour level
Andersson E; Johansson CC; Villabona L; Kanter L; Helgadottir H; Dalianis T; Bergfeldt K; Seliger B; Ferrone S; Kiessling R; Masucci GV
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(18)
Lack of p21/Waf-1 expression and lymphocyte infiltration in primary ovarian cancer correlate with the somatic HLA-A2 expression
Andersson E; Villabona L; Kanter L; Gamzatova Z; Kiessling R; Dalianis T; Bergfeldt K; Masucci GV
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16):478S
Human leucocyte antigen (HLA) A2 phenotype incidence in patients with advanced ovarian cancer as negative clinical prognostic factor.
Masucci GV; Gamzatova Z; Villabona L; Dahgren L; Dalianis T; Åvall-Lundqvist E; Bergfeldt K
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(16):467S
High frequency of human leucocyte antigen (HLA) A2 reflects a poorer prognosis in a group of advanced ovarian cancer patients.
Bergfeldt K; Hising C; Gamzatova Z; Tholander B; Åvall-Lundqvist E; van der Zanden HGM; Masucci G
Conference publication: EJC SUPPLEMENTS. 2005;3(2):265-266
Human leukocyte antigen (HLA) a2 as a negative prognostic factor in ovarian cancer patients
Gamzatova Z; Villabona L; Dalianis T; Van der Zanden H; Tholander B; Hising C; Bergfeldt K; Masucci G
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(14):720S
Alternating temazolomide and low doses rIL-2 in patients with metastatic melanoma.: An open non-randomized phase I/II study.
Masucci GV; Djuren-Mårtensson E; Hansson J; Månsson-Brahme E; Ragnársson-Olding B; Wagenius G
Editorial comment: MEDICAL ONCOLOGY. 2002;19(4):195-196
Dendritic cells highly quoted on immunotherapy stock market
Masucci G
Editorial comment: MEDICAL ONCOLOGY. 1999;16(1):13-16
Will modern cancer vaccines reach clinical practice?
Masucci G
Review: CRITICAL REVIEWS IN ONCOGENESIS. 1999;10(1-2):83-127
Cells and cytokines in immunotherapy and gene therapy of cancer
Pawelec G; Rees RC; Kiessling R; Madrigal A; Dodi A; Baxevanis C; Gambacorti-Passerini C; Masucci G; Zeuthen J
Book chapter: MOLECULAR ONCOLOGY AND CLINICAL APPLICATIONS: MOLECULAR AND CELL BIOLOGY UPDATES. 1993;p. 253-259
GM-CSF Augments the IL-4 Induced Cytotoxic Activity of Human Peripheral Blood Mononuclear Cells in the Presence of the Mouse Monoclonal Antibody 17–1A
Reali E; Mellstedt H; Traniello S; Masucci G
Book chapter: T LYMPHOCYTES: NATO SCIENCE SERIES A:. 1992;p. 235-240
Oligoclonal T Cells Expressing the TCR V-ß 6 Gene Product Following IL-2 Culture of Ovarian Carcinoma Derived Lymphocytes
Halapi E; Jeddi-Tehrani M; Grunewald J; Andersson R; Hising C; Masucci G; Mellstedt H; Kiessling R
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1990;32(4):406
IMMUNOLOGICAL MONITORING OF PATIENTS WITH ADVANCED KIDNEY CANCER TREATED WITH LOW-DOSE CYCLOPHOSPHAMIDE, ALPHA-INTERFERON AND INTERLEUKIN-2
MASUCCI G; WERSALL P; MELLSTEDT H
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1990;32(4):392
ANTIIDIOTYPIC AND ANTI-ANTI-IDIOTYPIC RESPONSE IN PATIENTS TREATED WITH MURINE MONOCLONAL-ANTIBODIES (MAB 17-1A)
FRODIN JE; HAGSTROM B; LEFVERT AK; MASUCCI G; MELLSTEDT H
Book chapter: CANCER THERAPY. 1989;p. 42-50
Mab 17-1A Used for Therapy of Patients with Metastatic Colorectal Carcinomas
Mellstedt H; Frödin J-E; Masucci G; Lindemalm C; Wedelin C; Christensson B; Shetye J; Biberfeld P; Lefvert A-K; Pihlstedt P; Makower J; Harmenberg U; Wahren B; Ahlman B; Cedermark B; Erwald R; Magnusson I; Nathansson J; Rieger A
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1983;18(1):71
IMMUNE EFFECTOR MECHANISMS MAINTAINING EPSTEIN-BARR VIRUS LATENCY IN INVIVO
ERNBERG I; MASUCCI G; SZIGETY R; MASUCCI MG
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1983;18(1):72
INTERFERON MEDIATED MODULATION OF NK SENSITIVITY IN A HUMAN HYBRID CELL-LINE DURING SELECTION WITH NK-CELLS
GRONBERG A; KIESSLING R; MASUCCI G; KLEIN G
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1982;15(1):137
A RAPIDLY FATAL CASE OF CLL WITH T-SUPPRESSOR PHENOTYPE IN A FAMILY WITH INCREASED LEUKEMOGENESIS
MASUCCI G; BIBERFELD P; MELSTEDT H; OST A; WU Y; BIBERFELD G
Conference publication: PEDIATRIC RESEARCH. 1982;16(8):696
EPSTEIN-BARR VIRUS SPECIFIC CELL-MEDIATED IMMUNE-REACTIONS IN INFECTIOUS MONONUCLEOSIS, CERTAIN IMMUNODEFICIENCIES AND DURING IMMUNOSUPPRESSION
SZIGETI R; MASUCCI G; ERNBERG I; KLEIN G
Book chapter: NK CELLS AND OTHER NATURAL EFFECTOR CELLS. 1982;p. 91-98
HUMAN BLOOD LYMPHOCYTE SUBSETS CHARACTERIZED BY MONOCLONAL REAGENTS Supported by Grant No 5 R01 CA-25250-02 awarded by the National Cancer Institute DHEW and by the Swedish Cancer Society.
Masucci G; Masucci MG; Bejarano MT; Klein E
Book chapter: NK CELLS AND OTHER NATURAL EFFECTOR CELLS. 1982;p. 475-482
EFFECT OF IFN AND PHA ON THE CYTOTOXIC ACTIVITY OF BLOOD LYMPHOCYTE SUBSETS
Masucci MG; Masucci G; Bejarano MT; Klein E
Book chapter: INTERFERON: CONTRIBUTIONS TO ONCOLOGY. 1982;p. 30-41
Effect of Interferon on Certain Cellular Immune Functions
Masucci MG; Klein E; Masucci G; Szigeti R; Vanky F
Book chapter: NATURAL CELL-MEDIATED IMMUNITY AGAINST TUMORS. 1980;p. 909-920
NATURAL AND ACTIVATED LYMPHOCYTE KILLERS WHICH AFFECT TUMOR CELLS11The work of the authors referred to was supported by Grant Number 1 R01 CA25250-01, awarded by the National Cancer Institute, DREW and by the Swedish Cancer Society.
Klein E; Masucci MG; Masucci G; Vanky F
Conference publication: ANNALI SCLAVO. COLLANA MONOGRAFICA. 1974;16(4):424-425
CHARACTERIZATION OF POLYKARYOCYTOGENIC AND CYTOAGGREGATING MUTANTS OF HERPES-SIMPLEX VIRUS - PRELIMINARY DATA
CASSAI E; MANSERVIGI R; MASUCCI G; RONCARATI E; TERNI M
Conference publication: ANNALI SCLAVO. COLLANA MONOGRAFICA. 1974;16(4):424
COMPARISON OF VHS-1 PROTEINS IN POLYACRYLAMIDE-GEL
CASSAI E; ROIZMAN B
Show more

Grants

Gustaf V:e Jubileum Fond (Radiumhemmet Fonder)

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2024-2027

Supervisor

Hannah Björn Andtback, 2022

About me

Research

Articles

All other publications

Grants

Employments

Supervisor

News from KI

Events from KI